<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="gsd1" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">gsd1</book-part-id>
      <title-group>
        <title>Glycogen Storage Disease Type I</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bali</surname>
            <given-names>Deeksha S</given-names>
          </name>
          <degrees>PhD</degrees>
          <aff>Division of Medical Genetics<break/>Department of Pediatrics<break/>Duke University Medical Center<break/>Durham, North Carolina</aff>
          <email>dbali@duke.edu</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Chen</surname>
            <given-names>Yuan-Tsong</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <aff>Division of Medical Genetics<break/>Department of Pediatrics<break/>Duke University Medical Center<break/>Durham, North Carolina</aff>
          <email>chen0010@mc.duke.edu</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Austin</surname>
            <given-names>Stephanie</given-names>
          </name>
          <degrees>MS, MA, CGC</degrees>
          <aff>Division of Medical Genetics<break/>Department of Pediatrics<break/>Duke University Medical Center<break/>Durham, North Carolina</aff>
          <email>stephanie.austin@duke.edu</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Goldstein</surname>
            <given-names>Jennifer L</given-names>
          </name>
          <degrees>PhD, MS, CGC</degrees>
          <aff>Division of Medical Genetics<break/>Department of Pediatrics<break/>Duke University Medical Center<break/>Durham, North Carolina</aff>
          <email>jennifer.goldstein@duke.edu</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date date-type="created">
          <day>19</day>
          <month>4</month>
          <year>2006</year>
        </date>
        <date date-type="updated">
          <day>25</day>
          <month>8</month>
          <year>2016</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="nkh" document-type="chapter">Glycine Encephalopathy</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="gsd3" document-type="chapter">Glycogen Storage Disease Type III</related-object>
      <abstract id="gsd1.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Glycogen storage disease type I (GSDI) is characterized by accumulation of glycogen and fat in the liver and kidneys, resulting in hepatomegaly and renomegaly. The two subtypes (GSDIa and GSDIb) are clinically indistinguishable. Some untreated neonates present with severe hypoglycemia; more commonly, however, untreated infants present at age three to four months with hepatomegaly, lactic acidosis, hyperuricemia, hyperlipidemia, hypertriglyceridemia, and/or hypoglycemic seizures. Affected children typically have doll-like faces with fat cheeks, relatively thin extremities, short stature, and protuberant abdomen. Xanthoma and diarrhea may be present. Impaired platelet function can lead to a bleeding tendency with frequent epistaxis. Untreated GSDIb is associated with impaired neutrophil and monocyte function as well as chronic neutropenia after the first few years of life, all of which result in recurrent bacterial infections and oral and intestinal mucosal ulcers. Long-term complications of untreated GSDI include growth retardation resulting in short stature, osteoporosis, delayed puberty, gout, renal disease, pulmonary hypertension, hepatic adenomas with potential for malignant transformation, polycystic ovaries, pancreatitis, and changes in brain function. Normal growth and puberty is expected in treated children. Most affected individuals live into adulthood.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of GSDI is established in a proband by identification of biallelic pathogenic variants in either <italic toggle="yes">G6PC</italic> or <italic toggle="yes">SLC37A4.</italic> Deficient hepatic enzyme activity (glucose-6-phosphatase catalytic activity or glucose-6-phosphate exchanger SLC37A4 activity) from a liver biopsy specimen establishes the diagnosis if molecular genetic testing is inconclusive.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Medical nutritional therapy to maintain normal blood glucose levels, prevent hypoglycemia, and provide optimal nutrition for growth and development; allopurinol to prevent gout when dietary therapy fails to completely normalize blood uric acid concentration; lipid-lowering medications for elevated lipid levels despite good metabolic control; citrate supplementation to help prevent development of urinary calculi or ameliorate nephrocalcinosis; angiotensin-converting enzyme (ACE) inhibitors to treat microalbuminuria; kidney transplantation for end-stage renal disease (ESRD); surgery or other interventions such as percutaneous ethanol injections and radiofrequency ablation for hepatic adenomas; liver transplantation for those individuals refractory to medical treatment; and treatment with human granulocyte colony-stimulating factor (G-CSF) for recurrent infections.</p>
          <p><italic toggle="yes">Prevention of secondary complications:</italic> Improve hyperuricemia and hyperlipidemia and maintain normal renal function to prevent development of renal disease; maintain lipid levels within the normal range to prevent atherosclerosis and pancreatitis.</p>
          <p><italic toggle="yes">Surveillance:</italic> Annual ultrasound examination of the kidneys after the first decade of life; liver ultrasound every 12 to 24 months until age 16 years; in individuals age 16 years and older, liver CT or MRI with contrast every six to 12 months to monitor for hepatic adenomas; liver ultrasound or MRI examinations (depending on age) every three to six months if hepatic adenoma is detected; hepatic profile (AST, ALT, albumin, bilirubin, PT/INR, aPTT) and serum creatinine every six to 12 months; complete blood count every three months for those on G-CSF; imaging with measurement of the spleen for those on G-CSF; systemic blood pressure at every clinic visit beginning in infancy; echocardiography every three years beginning at age ten years (or earlier if symptoms are present) to screen for pulmonary hypertension; routine monitoring of vitamin D levels.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Diet should be low in fructose and sucrose; galactose and lactose intake should be limited to one serving per day; combined oral contraception should be avoided in women, particularly those with adenomas.</p>
          <p><italic toggle="yes">Evaluation of relatives at risk:</italic> Molecular genetic testing (if the family-specific pathogenic variants are known) and/or evaluation by a metabolic physician soon after birth (if the family-specific pathogenic variants are not known) allows for early diagnosis and treatment of sibs at risk for GSDI.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>GSDI is inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Heterozygotes (carriers) are asymptomatic. Carrier testing for at-risk family members and prenatal diagnosis for pregnancies at increased risk are possible if both pathogenic variants have been identified in an affected family member.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="gsd1.Diagnosis">
        <title>Diagnosis</title>
        <p>The two major subtypes of glycogen storage disease type I (GSDI) are:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>GSD type Ia,</bold> caused by the deficiency of glucose-6-phosphatase (G6Pase) catalytic activity;</p>
          </list-item>
          <list-item>
            <p><bold>GSD type Ib,</bold> caused by a defect in glucose-6-phosphate exchanger SLC37A4 (transporter).</p>
          </list-item>
        </list>
        <p>The lack of either G6Pase catalytic activity or glucose-6-phosphate exchanger SLC37A4 (transporter) activity in the liver leads to inadequate conversion of glucose-6-phosphate into glucose through normal glycogenolysis and gluconeogenesis pathways, resulting in severe hypoglycemia and many other signs and symptoms of the GSDI disorders.</p>
        <p>Guidelines for diagnosis and management have been published by the American College of Medical Genetics and Genomics [<xref ref-type="bibr" rid="gsd1.REF.kishnani.2014.e1">Kishnani et al 2014</xref>] (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.nature.com/gim/journal/v16/n11/full/gim2014128a.html">full text</ext-link>).</p>
        <sec id="gsd1.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p>GSDI <bold>should be suspected</bold> in individuals with the following clinical, laboratory, and histopathologic features.</p>
          <p><bold>Clinical findings.</bold> Signs of hypoglycemia, hepatomegaly, and growth failure</p>
          <p>
            <bold>Laboratory findings</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Hypoglycemia.</bold> Fasting blood glucose concentration &#x0003c;60 mg/dL (reference range: 70-120 mg/dL)</p>
            </list-item>
            <list-item>
              <p><bold>Lactic acidosis.</bold> Blood lactate &#x0003e;2.5 mmol/L (reference range: 0.5-2.2 mmol/L)</p>
            </list-item>
            <list-item>
              <p><bold>Hyperuricemia.</bold> Blood uric acid &#x0003e;5.0 mg/dL (reference range: 2.0-5.0 mg/dL)</p>
            </list-item>
            <list-item>
              <p>Hyperlipidemia</p>
              <list list-type="bullet">
                <list-item>
                  <p>Triglycerides &#x0003e;250 mg/dL (reference range: 150-200 mg/dL); hypertriglyceridemia causes the plasma to appear &#x0201c;milky.&#x0201d;</p>
                </list-item>
                <list-item>
                  <p>Cholesterol &#x0003e;200 mg/dL (reference range: 100-200 mg/dL)</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p><bold>Glucagon or epinephrine challenge test.</bold> Administration of glucagon or epinephrine causes little or no increase in blood glucose concentration, but both increase serum lactate concentrations significantly.</p>
            </list-item>
          </list>
          <p><bold>Histopathologic liver findings.</bold> Distention of the liver cells by glycogen and fat; PAS positive and diastase sensitive glycogen that is uniformly distributed within the cytoplasm; normal or only modestly increased glycogen as compared with that seen in other liver GSDs (especially GSDIII and GSDIX); and large and numerous lipid vacuoles. Fibrosis and cirrhosis do not occur in GSDI.</p>
          <p>Note: As liver biopsy is invasive, it should only be done when a diagnosis cannot be made using molecular genetic testing (see <xref ref-type="sec" rid="gsd1.Establishing_the_Diagnosis">Establishing the Diagnosis</xref>). Liver tissue may be obtained at the same time as another surgery (e.g., G-tube placement) as a snap-frozen liver sample and diagnosis can be made by measuring G6Pase enzyme activity; however, G6Pase enzyme activity on a piece of snap-frozen liver biopsy tissue will not detect GSDIb.</p>
        </sec>
        <sec id="gsd1.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p>The diagnosis of GSDI <bold>is established</bold> in a proband by identification of EITHER of the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Biallelic pathogenic variants in <italic toggle="yes">G6PC</italic> (GSDIa) or <italic toggle="yes">SLC37A4</italic> (GSDIb) on <xref ref-type="sec" rid="gsd1.Molecular_Genetic_Testing">molecular genetic testing</xref></p>
            </list-item>
            <list-item>
              <p>Deficient <xref ref-type="sec" rid="gsd1.Enzyme_Activity_Assay">hepatic enzyme activity</xref></p>
            </list-item>
          </list>
          <sec id="gsd1.Molecular_Genetic_Testing">
            <title>Molecular Genetic Testing</title>
            <p>Molecular testing approaches can include serial single-gene testing, targeted analysis for pathogenic variants, use of a multi-gene panel, and more comprehensive genomic testing:</p>
            <list list-type="bullet">
              <list-item>
                <p><bold>Serial single-gene testing.</bold> Sequence analysis of <italic toggle="yes">G6PC</italic> is done first, followed by sequence analysis of <italic toggle="yes">SLC37A4</italic> if no <italic toggle="yes">G6PC</italic> pathogenic variants are identified and clinical indication of GSDI is strong. See <xref ref-type="table" rid="gsd1.T.molecular_genetic_testing_used_in">Table 1</xref>.</p>
              </list-item>
              <list-item>
                <p>Targeted analysis</p>
                <list list-type="bullet">
                  <list-item>
                    <p>For <italic toggle="yes">G6PC</italic> pathogenic variant <xref ref-type="table" rid="gsd1.T.g6pc_pathogenic_variants_discusse">p.Arg83Cys</xref> can be performed first in individuals of Ashkenazi Jewish ancestry [<xref ref-type="bibr" rid="gsd1.REF.ekstein.2004.162">Ekstein et al 2004</xref>];</p>
                  </list-item>
                  <list-item>
                    <p>For <italic toggle="yes">G6PD</italic> pathogenic variant <xref ref-type="table" rid="gsd1.T.g6pc_pathogenic_variants_discusse">p.Gln347Ter</xref> can be performed first in individuals of Old Order Amish ancestry.</p>
                  </list-item>
                </list>
              </list-item>
              <list-item>
                <p><bold>A multi-gene panel</bold> that includes <italic toggle="yes">G6PC</italic>, <italic toggle="yes">SLC37A4</italic> and other genes of interest (see <xref ref-type="sec" rid="gsd1.Differential_Diagnosis">Differential Diagnosis</xref>) may also be considered. Note: The genes included and the sensitivity of multi-gene panels vary by laboratory and over time.</p>
              </list-item>
              <list-item>
                <p><bold>More comprehensive genomic testing</bold> (when available) including whole-exome sequencing (WES) and whole-genome sequencing (WGS) may be considered if serial single-gene testing (and/or use of a multi-gene panel) fails to confirm a diagnosis in an individual with features of GSDI. For more information on comprehensive genome sequencing click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.Comprehensive_Genome_Sequencing" object-type="sec">here</related-object>.</p>
              </list-item>
            </list>
          </sec>
          <sec id="gsd1.Enzyme_Activity_Assay">
            <title>Enzyme Activity Assay</title>
            <p>A sample of 15-20 mg of snap-frozen liver obtained by percutaneous or open biopsy should be shipped on dry ice via overnight delivery to the clinical diagnostic laboratory.</p>
            <list list-type="bullet">
              <list-item>
                <p><bold>Glucose-6-phosphatase (G6Pase) catalytic activity.</bold> The normal G6Pase enzyme activity level in liver is 3.50&#x000b1;0.8 &#x000b5;mol/min/g tissue:</p>
                <list list-type="bullet">
                  <list-item>
                    <p>In most individuals with GSDIa, the G6Pase enzyme activity is &#x0003c;10% of normal.</p>
                  </list-item>
                  <list-item>
                    <p>In rare individuals with milder clinical manifestations, the G6Pase enzyme activity can be higher (&#x0003e;1.0 &#x000b5;mol/min/g tissue and &#x0003c;2.0 &#x000b5;mol/min/g tissue).</p>
                  </list-item>
                </list>
              </list-item>
              <list-item>
                <p><bold>Glucose-6-phosphate exchanger SLC37A4 (transporter) activity.</bold> G6P exchanger SLC37A4 activity using an in vitro assay is difficult to measure in frozen liver; therefore, fresh (unfrozen) liver is often needed to assay enzyme activity accurately. As a result, most clinical diagnostic laboratories refrain from offering this enzyme activity assay.</p>
              </list-item>
            </list>
            <p>Note: Because of its relatively high sensitivity, molecular genetic testing is increasingly the preferred confirmatory test when weighed against the need for liver biopsy to determine the level of enzyme activity. However liver biopsy can additionally be used to obtain histology and electronic micrographic information, which along with enzyme analysis can be used to further investigate pathology associated with variants of uncertain significance (VOUS) found on genetic testing.</p>
            <table-wrap id="gsd1.T.molecular_genetic_testing_used_in" orientation="portrait" position="anchor">
              <label>Table 1. </label>
              <caption>
                <p>Molecular Genetic Testing Used in Glycogen Storage Disease Type I</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_gsd1.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_gsd1.T.molecular_genetic_testing_used_in_1_1_1_1">Gene&#x000a0;<sup>1</sup></th>
                    <th id="hd_h_gsd1.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_gsd1.T.molecular_genetic_testing_used_in_1_1_1_2">Proportion of GSDI Attributed to Pathogenic Variants in This Gene</th>
                    <th id="hd_h_gsd1.T.molecular_genetic_testing_used_in_1_1_1_3" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">Proportion of Pathogenic Variants&#x000a0;<sup>2</sup> Detected by Test Method</th>
                  </tr>
                  <tr>
                    <th headers="hd_h_gsd1.T.molecular_genetic_testing_used_in_1_1_1_3" id="hd_h_gsd1.T.molecular_genetic_testing_used_in_1_1_2_1" valign="middle" colspan="1" align="left" scope="colgroup" rowspan="1">Sequence analysis&#x000a0;<sup>3</sup></th>
                    <th headers="hd_h_gsd1.T.molecular_genetic_testing_used_in_1_1_1_3" id="hd_h_gsd1.T.molecular_genetic_testing_used_in_1_1_2_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene-targeted deletion/duplication analysis&#x000a0;<sup>4</sup></th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_gsd1.T.molecular_genetic_testing_used_in_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                      <italic toggle="yes">G6PC</italic>
                    </td>
                    <td headers="hd_h_gsd1.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">80%</td>
                    <td headers="hd_h_gsd1.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_gsd1.T.molecular_genetic_testing_used_in_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">~95%&#x000a0;<sup>5</sup></td>
                    <td headers="hd_h_gsd1.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_gsd1.T.molecular_genetic_testing_used_in_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">2 individuals&#x000a0;<sup>6</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_gsd1.T.molecular_genetic_testing_used_in_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                      <italic toggle="yes">SLC37A4</italic>
                    </td>
                    <td headers="hd_h_gsd1.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">20%</td>
                    <td headers="hd_h_gsd1.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_gsd1.T.molecular_genetic_testing_used_in_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">~95%</td>
                    <td headers="hd_h_gsd1.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_gsd1.T.molecular_genetic_testing_used_in_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Unknown&#x000a0;<sup>7</sup></td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="gsd1.TF.1.1">
                  <label>1. </label>
                  <p>See <related-object source-id="gene" document-id="gsd1" object-id="gsd1.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
                </fn>
                <fn id="gsd1.TF.1.2">
                  <label>2. </label>
                  <p>See <xref ref-type="sec" rid="gsd1.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
                </fn>
                <fn id="gsd1.TF.1.3">
                  <label>3. </label>
                  <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
                </fn>
                <fn id="gsd1.TF.1.4">
                  <label>4. </label>
                  <p>Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.</p>
                </fn>
                <fn id="gsd1.TF.1.5">
                  <label>5. </label>
                  <p><xref ref-type="bibr" rid="gsd1.REF.rake.2000.322">Rake et al [2000]</xref>, <xref ref-type="bibr" rid="gsd1.REF.seydewitz.2000.115">Seydewitz &#x00026; Matern [2000]</xref> (in 40 affected individuals)</p>
                </fn>
                <fn id="gsd1.TF.1.6">
                  <label>6. </label>
                  <p>Although the frequency of (multi)exon deletions is unknown, very few have been reported in either of these genes [<xref ref-type="bibr" rid="gsd1.REF.janecke.2000.285">Janecke et al 2000</xref>, <xref ref-type="bibr" rid="gsd1.REF.wang.2012.795">Wang et al 2012</xref>].</p>
                </fn>
                <fn id="gsd1.TF.1.7">
                  <label>7. </label>
                  <p>No data on detection rate of gene-targeted deletion/duplication analysis are available.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </sec>
        </sec>
      </sec>
      <sec id="gsd1.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="gsd1.Clinical_Description">
          <title>Clinical Description</title>
          <p>The clinical manifestations of glycogen storage disease type I (GSDI) are growth retardation leading to short stature and accumulation of glycogen and fat in the liver and kidneys, which result in hepatomegaly and renomegaly, respectively [<xref ref-type="bibr" rid="gsd1.REF.kishnani.2014.e1">Kishnani et al 2014</xref>].</p>
          <p>Although some neonates present with severe hypoglycemia, more commonly untreated infants present at age three to four months with hepatomegaly, lactic acidosis, hyperuricemia, hyperlipidemia, hypertriglyceridemia, and/or hypoglycemic seizures. Hypoglycemia and lactic acidosis can develop after a short fast (2-4 hours).</p>
          <p>Untreated children typically have doll-like faces with fat cheeks, relatively thin extremities, short stature, and protuberant abdomen caused by massive hepatomegaly. The spleen is of normal size. Xanthoma and diarrhea may be present. Impaired platelet function can lead to a bleeding tendency, making epistaxis a frequent problem.</p>
          <p>In addition to the above findings, untreated GSDIb is associated with chronic neutropenia and impaired neutrophil and monocyte function. Neutropenia is noted typically after the first few years of life, resulting in recurrent bacterial infections and oral and intestinal mucosal ulcers [<xref ref-type="bibr" rid="gsd1.REF.visser.1998.227">Visser et al 1998</xref>, <xref ref-type="bibr" rid="gsd1.REF.visser.2002a.261">Visser et al 2002a</xref>]. Oral manifestations such as ulcers, gingivitis, periodontal disease, bleeding diathesis, dental caries, and delayed dental maturation and eruption have been reported in a few affected individuals [<xref ref-type="bibr" rid="gsd1.REF.mortellaro.2005.45">Mortellaro et al 2005</xref>].</p>
          <p>Long-term complications of untreated GSDI include the following:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Short stature.</bold> Children with GSDI have poor growth and short stature in adulthood; however, with strict dietary regimens and control, growth and final adult stature have improved [<xref ref-type="bibr" rid="gsd1.REF.weinstein.2002.s35">Weinstein &#x00026; Wolfsdorf 2002</xref>, <xref ref-type="bibr" rid="gsd1.REF.mundy.2003.332">Mundy et al 2003</xref>, <xref ref-type="bibr" rid="gsd1.REF.kishnani.2014.e1">Kishnani et al 2014</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Osteoporosis.</bold> Frequent fractures and radiographic evidence of osteopenia are common. Bone mineral content can be significantly reduced even in prepubertal children [<xref ref-type="bibr" rid="gsd1.REF.schwahn.2002.350">Schwahn et al 2002</xref>, <xref ref-type="bibr" rid="gsd1.REF.visser.2002b.s83">Visser et al 2002b</xref>, <xref ref-type="bibr" rid="gsd1.REF.wolfsdorf.2002.308">Wolfsdorf 2002</xref>, <xref ref-type="bibr" rid="gsd1.REF.rake.2003.371">Rake et al 2003</xref>, <xref ref-type="bibr" rid="gsd1.REF.cabreraabreu.2004.1">Cabrera-Abreu et al 2004</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Delayed puberty.</bold> Untreated affected individuals historically showed delayed onset of puberty; however, with adherence to a strict dietary regimen, age of onset of puberty can be normal [<xref ref-type="bibr" rid="gsd1.REF.sechi.2013.83">Sechi et al 2013</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Gout.</bold> Although hyperuricemia is present in young affected children, gout rarely develops in untreated children before puberty [<xref ref-type="bibr" rid="gsd1.REF.matern.2002.s10">Matern et al 2002</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Renal disease.</bold> Proteinuria, hypertension, renal stones, nephrocalcinosis, and altered creatinine clearance may occur in younger affected individuals. With disease progression, interstitial fibrosis becomes evident. Some individuals progress to end-stage renal disease (ESRD) and may require a renal transplant [<xref ref-type="bibr" rid="gsd1.REF.sim_es.2001.1277">Sim&#x000f6;es et al 2001</xref>, <xref ref-type="bibr" rid="gsd1.REF.weinstein.2002.s35">Weinstein &#x00026; Wolfsdorf 2002</xref>, <xref ref-type="bibr" rid="gsd1.REF.iida.2003.56">Iida et al 2003</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Systemic hypertension</bold> does not usually develop until the second decade or later and is often found in those individuals with GSDI who also have renal disease [<xref ref-type="bibr" rid="gsd1.REF.rake.2002.s20">Rake et al 2002</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Pulmonary hypertension.</bold> Overt pulmonary hypertension as a long-term complication of GSDI has been reported [<xref ref-type="bibr" rid="gsd1.REF.kishnani.1996.213">Kishnani et al 1996</xref>, <xref ref-type="bibr" rid="gsd1.REF.humbert.2002.s93">Humbert et al 2002</xref>]. Those at highest risk typically have a coexisting condition that also predisposes them to developing pulmonary hypertension [<xref ref-type="bibr" rid="gsd1.REF.pizzo.1980.341">Pizzo 1980</xref>, <xref ref-type="bibr" rid="gsd1.REF.furukawa.1990.102">Furukawa et al 1990</xref>, <xref ref-type="bibr" rid="gsd1.REF.hamaoka.1990.54">Hamaoka et al 1990</xref>, <xref ref-type="bibr" rid="gsd1.REF.bolz.1996.265">Bolz et al 1996</xref>, <xref ref-type="bibr" rid="gsd1.REF.kishnani.2014.e1">Kishnani et al 2014</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Hepatic adenomas with potential for malignant transformation.</bold> By the second or third decade of life, most affected individuals exhibit hepatic adenomas, a complication of which is intrahepatic hemorrhage. In some, the adenomas may undergo malignant transformation into hepatocellular carcinoma (HCC) [<xref ref-type="bibr" rid="gsd1.REF.kelly.2001.505">Kelly &#x00026; Poon 2001</xref>, <xref ref-type="bibr" rid="gsd1.REF.kudo.2001.65">Kudo 2001</xref>, <xref ref-type="bibr" rid="gsd1.REF.weinstein.2002.s35">Weinstein &#x00026; Wolfsdorf 2002</xref>, <xref ref-type="bibr" rid="gsd1.REF.franco.2005.153">Franco et al 2005</xref>]. Evidence for a relationship between poor metabolic control and the development of adenomas is conflicting [<xref ref-type="bibr" rid="gsd1.REF.di_rocco.2007.42">Di Rocco et al 2007</xref>, <xref ref-type="bibr" rid="gsd1.REF.wang.2011.442">Wang et al 2011</xref>, <xref ref-type="bibr" rid="gsd1.REF.kishnani.2014.e1">Kishnani et al 2014</xref>, <xref ref-type="bibr" rid="gsd1.REF.beegle.2015.23">Beegle et al 2015</xref>]. While it has been reported, the pathogenesis is likely to be multifactorial [<xref ref-type="bibr" rid="gsd1.REF.wang.2011.442">Wang et al 2011</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Pancreatitis,</bold> a secondary complication of hypertriglyceridemia, is seen in some affected individuals, particularly those in poor dietary compliance.</p>
            </list-item>
            <list-item>
              <p><bold>Neurocognitive effects.</bold> Changes in IQ, MRI findings, and EEG were found to correlate with the frequency of hypoglycemic episodes, particularly in those in poor dietary compliance [<xref ref-type="bibr" rid="gsd1.REF.melis.2004.637">Melis et al 2004</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Anemia</bold> is a common problem in individuals with GSDI [<xref ref-type="bibr" rid="gsd1.REF.rake.2002.s20">Rake et al 2002</xref>], although the pathophysiology appears to differ in individuals with GSDIa and those with GSDIb [<xref ref-type="bibr" rid="gsd1.REF.wang.2012.795">Wang et al 2012</xref>]: those with GSDIa and severe anemia are likely to have hepatic adenomas, while those with GSDIb and severe anemia may have enterocolitis [<xref ref-type="bibr" rid="gsd1.REF.wang.2012.795">Wang et al 2012</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Vitamin D deficiency.</bold> In one study, 16/26 affected individuals had suboptimal levels of vitamin D suggesting that 25(OH)-vitamin D levels should be measured on a routine basis [<xref ref-type="bibr" rid="gsd1.REF.banugaria.2010.434">Banugaria et al 2010</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Polycystic ovaries.</bold> Virtually all affected females have ultrasound findings consistent with polycystic ovaries. While this may affect ovulation and fertility in some females, in general fertility does not appear to be reduced [<xref ref-type="bibr" rid="gsd1.REF.sechi.2013.83">Sechi et al 2013</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Irregular menstrual cycles.</bold> About half of women with GSDI were found to have irregular menstrual cycles [<xref ref-type="bibr" rid="gsd1.REF.sechi.2013.83">Sechi et al 2013</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Bleeding diathesis.</bold> Some individuals have features suggestive of a von Willebrand disease-like defect with reduced von Willebrand factor antigen and/or dysfunctional von Willebrand factor. Manifestations include epistaxis, easy bruising, menorrhagia, and bleeding during surgical procedures. Menorrhagia appears to be a problem for reproductive-age females with GSDI [<xref ref-type="bibr" rid="gsd1.REF.austin.2013.1246">Austin et al 2013</xref>]. This issue should be addressed when reviewing the clinical history of reproductive-age females with GSDI. Referral to a gynecologist for management should be made when appropriate.</p>
            </list-item>
          </list>
          <p>In addition, individuals with GSDIb may develop the following:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Neutropenia and impaired neutrophil function.</bold> Neutropenia and recurrent infections are common in individuals with GSDIb and can also occur in a small subset of individuals with GSDIa [<xref ref-type="bibr" rid="gsd1.REF.weston.2000.329">Weston et al 2000</xref>]. Evidence suggests that the neutropenia in those with GSDIb may be caused by increased apoptosis and migration of the neutrophils to inflamed tissues rather than by impairment in maturation [<xref ref-type="bibr" rid="gsd1.REF.visser.2012.287">Visser et al 2012</xref>, <xref ref-type="bibr" rid="gsd1.REF.kishnani.2014.e1">Kishnani et al 2014</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Inflammatory bowel disease/enterocolitis</bold> is common in individuals with GSDIb [<xref ref-type="bibr" rid="gsd1.REF.visser.2002b.s83">Visser et al 2002b</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Thyroid autoimmunity.</bold> The prevalence of thyroid autoimmunity and hypothyroidism has been found to be increased in individuals with GSDIb [<xref ref-type="bibr" rid="gsd1.REF.melis.2007.300">Melis et al 2007</xref>].</p>
            </list-item>
          </list>
          <p>In the past, many individuals with GSDI who were untreated died at a young age and the prognosis was guarded in survivors. However, early diagnosis and treatment have improved prognosis. Normal growth and puberty may be expected in treated children, and most affected individuals live into adulthood. However, it is not known if all long-term secondary complications can be avoided by good metabolic control. Some individuals treated early develop hepatic adenoma and proteinuria in adulthood.</p>
        </sec>
        <sec id="gsd1.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>No strong genotype-phenotype correlations have been identified for GSDI [<xref ref-type="bibr" rid="gsd1.REF.matern.2002.s10">Matern et al 2002</xref>, <xref ref-type="bibr" rid="gsd1.REF.chou.2008.921">Chou &#x00026; Mansfield 2008</xref>, <xref ref-type="bibr" rid="gsd1.REF.eminoglu.2013.346">Eminoglu et al 2013</xref>, <xref ref-type="bibr" rid="gsd1.REF.kishnani.2014.e1">Kishnani et al 2014</xref>].</p>
          <p><bold><italic toggle="yes">G6PC</italic>.</bold> Two case reports suggested that individuals with GSDIa who are homozygous for the <xref ref-type="table" rid="gsd1.T.g6pc_pathogenic_variants_discusse">c.648G&#x0003e;T</xref> pathogenic splicing variant may be at increased risk of developing hepatocellular carcinoma (HCC) [<xref ref-type="bibr" rid="gsd1.REF.nakamura.1999.553">Nakamura et al 1999</xref>, <xref ref-type="bibr" rid="gsd1.REF.matern.2002.s10">Matern et al 2002</xref>]. This pathogenic variant is the most common cause of GSDIa in individuals of Japanese descent. Of 19 Japanese adults who were homozygous for c.648G&#x0003e;T, three had HCC, one had cholangiocellular carcinoma, and seven had hepatic adenoma [<xref ref-type="bibr" rid="gsd1.REF.nakamura.2001.1402">Nakamura et al 2001</xref>]. A study of 40 individuals who were homozygous for this pathogenic variant found that c.648G&#x0003e;T is associated with a milder phenotype with respect to hypoglycemia [<xref ref-type="bibr" rid="gsd1.REF.akanuma.2000.107">Akanuma et al 2000</xref>, <xref ref-type="bibr" rid="gsd1.REF.chou.2008.921">Chou &#x00026; Mansfield 2008</xref>].</p>
          <p>Individuals with GSDIa who are homozygous for the pathogenic variant <xref ref-type="table" rid="gsd1.T.g6pc_pathogenic_variants_discusse">c.562G&#x0003e;C</xref> were reported to have a GSDIb-like phenotype with mild neutropenia [<xref ref-type="bibr" rid="gsd1.REF.weston.2000.329">Weston et al 2000</xref>, <xref ref-type="bibr" rid="gsd1.REF.chou.2008.921">Chou &#x00026; Mansfield 2008</xref>]. This phenotype was not observed in an individual who was compound heterozygous for this pathogenic variant [<xref ref-type="bibr" rid="gsd1.REF.eminoglu.2013.346">Eminoglu et al 2013</xref>].</p>
          <p><bold><italic toggle="yes">SLC37A4.</italic></bold> No clear phenotype-genotype correlations have been found in GSDIb [<xref ref-type="bibr" rid="gsd1.REF.melis.2005.501">Melis et al 2005</xref>].</p>
        </sec>
        <sec id="gsd1.Nomenclature">
          <title>Nomenclature</title>
          <p>G6Pase is a multi-component enzyme complex often referred to as the G6Pase system. Some authors preferred to classify GSD type I into 'type Ia' and 'type I non-a' phenotypes because most individuals previously classified as having GSDIc and Id have now been shown to have pathogenic variants in <italic toggle="yes">SLC37A4</italic> [<xref ref-type="bibr" rid="gsd1.REF.veigadacunha.1998.976">Veiga-da-Cunha et al 1998</xref>, <xref ref-type="bibr" rid="gsd1.REF.veigadacunha.1999.717">Veiga-da-Cunha et al 1999</xref>, <xref ref-type="bibr" rid="gsd1.REF.veigadacunha.2000.314">Veiga-da-Cunha et al 2000</xref>]. However, all newer publications prefer to classify the GSDI subtypes as GSDIa and GSDIb. Hence, the classification of GSDI into four subtypes no longer exists.</p>
          <p>Historically, GSDI is also referred to as von Gierke disease after Dr. Edgar von Gierke, who first described the disease in 1929.</p>
        </sec>
        <sec id="gsd1.Prevalence">
          <title>Prevalence</title>
          <p>The overall incidence of GSDI is one in 100,000.</p>
          <p>GSDIa is the most common GSD subtype in individuals of European descent.</p>
          <p>In Ashkenazi Jews the estimated carrier frequency of the most common pathogenic variant (<xref ref-type="table" rid="gsd1.T.g6pc_pathogenic_variants_discusse">p.Arg83Cys</xref>) is 1.4% and disease prevalence is one in 20,000.</p>
          <p>The increased frequency of some pathogenic variants in different ethnic groups (e.g., <xref ref-type="table" rid="gsd1.T.g6pc_pathogenic_variants_discusse">c.648G&#x0003e;T</xref> in 88% of affected individuals of Japanese ancestry, <xref ref-type="table" rid="gsd1.T.g6pc_pathogenic_variants_discusse">c.379_380dupTA</xref> in 50% of affected Hispanic Americans) may reflect population-specific differences in disease prevalence [<xref ref-type="bibr" rid="gsd1.REF.janecke.2001.117">Janecke et al 2001</xref>, <xref ref-type="bibr" rid="gsd1.REF.chou.2002.121">Chou et al 2002</xref>, <xref ref-type="bibr" rid="gsd1.REF.ekstein.2004.162">Ekstein et al 2004</xref>].</p>
        </sec>
      </sec>
      <sec id="gsd1.Genetically_Related_Allelic_Disorde">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No phenotypes other than those discussed in this <italic toggle="yes">GeneReview</italic> are known to be associated with pathogenic variants in <italic toggle="yes">G6PC</italic> or <italic toggle="yes">SLC37A4</italic>.</p>
      </sec>
      <sec id="gsd1.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p><related-object link-type="booklink" source-id="gene" document-id="gsd3" document-type="chapter">Glycogen storage disease type III</related-object> (GSDIII) (debranching enzyme deficiency) is clinically similar to GSDI in infancy. With age, however, clinical findings and biochemical work up can differentiate between the two disorders. Major manifestations of GSDIII include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypoglycemia that improves with age</p>
          </list-item>
          <list-item>
            <p>Hepatomegaly caused by abnormal glycogen accumulation</p>
          </list-item>
          <list-item>
            <p>Hyperlipidemia</p>
          </list-item>
          <list-item>
            <p>Skeletal myopathy and increased serum creatine kinase concentration (in GSDIIIa only)</p>
          </list-item>
        </list>
        <p>In contrast to GSDI, GSDIII is characterized by the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Normal glucagon response two hours after a carbohydrate meal</p>
          </list-item>
          <list-item>
            <p>Elevated liver transaminases</p>
          </list-item>
          <list-item>
            <p>Myopathy/cardiomyopathy (GSDIIIa only)</p>
          </list-item>
          <list-item>
            <p>Absence of renomegaly</p>
          </list-item>
        </list>
        <p>Other conditions that can present clinically like GSDI include <related-object link-type="booklink" source-id="gene" document-id="gsd6" document-type="chapter">GSD type VI</related-object>, <related-object link-type="booklink" source-id="gene" document-id="gsd9" document-type="chapter">GSD type IX</related-object> (<related-object link-type="booklink" source-id="gene" document-id="gsd9" document-type="chapter">phosphorylase kinase deficiency</related-object>), fructose-1,6-bisphosphatase deficiency (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/229700">OMIM</ext-link>), diabetes mellitus, and Niemann-Pick type B (see <related-object link-type="booklink" source-id="gene" document-id="npab" document-type="chapter">Acid Sphingomyelinase Deficiency</related-object>).</p>
      </sec>
      <sec id="gsd1.Management">
        <title>Management</title>
        <sec id="gsd1.Evaluations_Following_Initial_Diagn">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with glycogen storage disease type I (GSDI), the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Serum/plasma concentration of glucose, lactic acid, uric acid, 25(OH)-vitamin D, and lipids including cholesterol and triglycerides</p>
            </list-item>
            <list-item>
              <p>Complete blood count to evaluate for neutropenia in individuals with GSDIb and those with GSDIa due to homozygosity for the <xref ref-type="table" rid="gsd1.T.g6pc_pathogenic_variants_discusse">p.Gly188Arg</xref> pathogenic variant in <italic toggle="yes">G6PC</italic></p>
            </list-item>
            <list-item>
              <p>Measurement of length or height and weight and calculation of body mass index</p>
            </list-item>
            <list-item>
              <p>Evaluation of nutritional status</p>
            </list-item>
            <list-item>
              <p>Liver imaging to evaluate for hepatomegaly</p>
            </list-item>
            <list-item>
              <p>Liver function tests</p>
            </list-item>
            <list-item>
              <p>Kidney imaging to evaluate for renomegaly</p>
            </list-item>
            <list-item>
              <p>Kidney function tests</p>
            </list-item>
            <list-item>
              <p>Platelet function assay to evaluate platelet function</p>
            </list-item>
            <list-item>
              <p>Measurement of bone density (after the first decade)</p>
            </list-item>
            <list-item>
              <p>Screening to detect systemic and pulmonary hypertension</p>
            </list-item>
            <list-item>
              <p>Metabolic specialist consultation</p>
            </list-item>
            <list-item>
              <p>Consultation with a clinical geneticist and/or genetic counselor</p>
            </list-item>
          </list>
        </sec>
        <sec id="gsd1.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Guidelines for management have been published by the American College of Medical Genetics [<xref ref-type="bibr" rid="gsd1.REF.kishnani.2014.e1">Kishnani et al 2014</xref>] (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.nature.com/gim/journal/v16/n11/full/gim2014128a.html">full text</ext-link>).</p>
          <p>Treatment includes care by a <bold>metabolic team</bold> familiar with the medical issues associated with long-term management of persons with GSD. At a minimum, such a team should include the following:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Metabolic specialist</bold> familiar with the multisystem nature of GSDI. This individual should monitor current medical issues while providing anticipatory guidance and feedback regarding potential future medical issues (e.g., malignant transformation of liver adenomas, kidney stone management).</p>
            </list-item>
            <list-item>
              <p><bold>Metabolic nutritionist</bold> who monitors nutritional adequacy, weight management, food choices, and timing of cornstarch and food intake, and who works with the individual and/or family to assure understanding of the parameters of compliance at different life stages</p>
            </list-item>
            <list-item>
              <p><bold>Health care provider</bold> (nurse, genetic counselor, physician assistant) familiar with the inheritance of GSDI who can address questions related to implications of this diagnosis for other family members and future childbearing of the affected person. Such an individual may focus on health care compliance by assisting affected children to transition to independent understanding and management of their GSDI-related health care issues.</p>
            </list-item>
          </list>
          <p><bold>Care teams</bold> often establish relationships with additional health care workers including:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Medical social worker</bold> to assist with formula acquisition and access to community-based services (e.g., access to regular exercise and physical activity plans) and provide early intervention for long-term health management and wellness;</p>
            </list-item>
            <list-item>
              <p><bold>Psychologist</bold> with experience in helping affected individuals cope with eating disorders and chronic illness.</p>
            </list-item>
          </list>
          <sec id="gsd1.Medical_Nutrition_Therapy_Goals">
            <title>Medical Nutrition Therapy Goals</title>
            <p><bold>Maintain</bold>
<bold>normal glucose levels</bold> and prevent hypoglycemia:</p>
            <list list-type="bullet">
              <list-item>
                <p><bold>Frequent daytime feedings.</bold> Small frequent meals and snacks high in complex carbohydrates with additional feedings between meals and before bedtime are recommended (monitoring of blood glucose concentration may help adjust feeding schedules to meet individual needs).</p>
              </list-item>
              <list-item>
                <p><bold>Nighttime intragastric continuous glucose infusion</bold> through a nasogastric tube or a gastrostomy tube. An optimal infusion should provide 8-10 mg/kg/min glucose in an infant and 6-8 mg/kg/min glucose in an older child.</p>
              </list-item>
              <list-item>
                <p><bold>Uncooked cornstarch</bold> orally can be started during infancy [<xref ref-type="bibr" rid="gsd1.REF.wolfsdorf.1999.136">Wolfsdorf &#x00026; Crigler 1999</xref>, <xref ref-type="bibr" rid="gsd1.REF.weinstein.2002.s35">Weinstein &#x00026; Wolfsdorf 2002</xref>]. Cornstarch should be given between meals or before bedtime so as not to interfere with appetite at meal time.</p>
                <list list-type="bullet">
                  <list-item>
                    <p>Argo<sup>&#x000ae;</sup> is the preferred brand in the United States in terms of both taste and sustainability. Other brands should be used with caution, and randomly switching between brands is not recommended. A modified cornstarch, waxy maize extended-release cornstarch, Glycosade<sup>&#x000ae;</sup>, is available in Europe and the United States for overnight treatment [<xref ref-type="bibr" rid="gsd1.REF.ross.2016.85">Ross et al 2016</xref>].</p>
                  </list-item>
                  <list-item>
                    <p>There is no consensus on the age at which cornstarch therapy should be initiated but a trial is often introduced between ages six months and one year. Amylase is required to digest cornstarch and may not be present until age two years.</p>
                  </list-item>
                  <list-item>
                    <p>The severity and recurrence of hypoglycemic episodes determines the timing of cornstarch therapy initiation via nasogastric tube or gastrostomy tube in infancy and childhood and oral ingestion in teenagers and adults.</p>
                  </list-item>
                  <list-item>
                    <p>Note: Recommendations for uncooked cornstarch dosing are: 1.6 g/kg body weight every four hours for infants, 1.7-2.5 g/kg body weight every six hours for young children through puberty, and 1.7-2.5 g/kg body weight given before bed time for adults. Dosing for modified cornstarch should be decided under the guidance of a metabolic treatment team using frequent glucose monitoring.</p>
                  </list-item>
                </list>
              </list-item>
            </list>
            <p><bold>Provide</bold>
<bold>optimal nutrition</bold> for growth and development:</p>
            <list list-type="bullet">
              <list-item>
                <p><bold>Complex carbohydrates</bold> (60%-70% of recommended total energy intake) including cornstarch and starches from whole-grain bread, rice, and potatoes for children and adolescents and rice cereals for infants</p>
                <p>Note: (1) Intake of sucrose and fructose should be restricted for infants and older children. Avoid sugar, fruits, fruit juice, high-fructose corn syrup, sorbitol, cane juice, and other foods that cannot be broken down into glucose. (2) Intake of lactose and galactose should be limited. One serving per day for an older child usually entails 1.5 ounces of cheese OR 1 cup of yogurt OR 1 cup of skim milk. (3) Blood glucose monitoring for hypoglycemia is important so that overtreatment with cornstarch may be avoided. If excess weight gain occurs, consider decreasing the amount of cornstarch gradually over time and mixing cornstarch in water instead of Prosobee<sup>&#x000ae;</sup> or Tolerex<sup>&#x000ae;</sup>.</p>
              </list-item>
              <list-item>
                <p><bold>Protein</bold> (10%-15% of recommended total energy intake) of high quality, high biologic value (e.g., protein low in fat). Soy formula (Prosobee<sup>&#x000ae;</sup>) and soy milk (lactose/galactose free) can be used both in infancy and childhood for carbohydrate and protein needs.</p>
                <p>Note: (1) Avoid soy milks that are sweetened with sucrose; the ones with rice syrup or brown rice syrup can be taken. (2) Soy milk mixed with cane sugar should be avoided.</p>
              </list-item>
              <list-item>
                <p><bold>Fat</bold> (10%-15% of recommended total energy intake) as part of a low-fat diet that includes heart-healthy fats such as canola oil and olive oil. Note: Families need explicit guidelines on fat intake as part of monitoring total energy intake and avoiding excessive weight gain.</p>
              </list-item>
              <list-item>
                <p><bold>Calcium and vitamin D supplements</bold> to support bone growth and mineralization. If the individual is not on calcium-fortified soy milk, calcium citrate or calcium carbonate with vitamin D is recommended to meet RDA for age needs and to prevent nutritional deficiencies.</p>
              </list-item>
              <list-item>
                <p><bold>Iron supplements</bold> in complete multivitamins with minerals (100% RDA iron and zinc) to avoid anemia and iron deficiency</p>
              </list-item>
            </list>
          </sec>
          <sec id="gsd1.Treatment_of_Other_Manifestations">
            <title>Treatment of Other Manifestations</title>
            <p><bold>Allopurinol,</bold> a xanthine oxidase inhibitor, is used to prevent gout when dietary therapy fails to completely normalize blood uric acid concentration, especially after puberty.</p>
            <p><bold>Lipid-lowering medications,</bold> such as HMG-CoA reductase inhibitors and fibrate (e.g., Lipitor<sup>&#x000ae;</sup>, gemfibrozil), are used when lipid levels remain elevated despite good metabolic control, especially after puberty.</p>
            <p><bold>Citrate supplementation</bold> may help prevent or ameliorate nephrocalcinosis and the development of urinary calculi.</p>
            <list list-type="bullet">
              <list-item>
                <p>In young children, an initial dose of 1 mEq/kg/day in liquid form divided into three doses should be instituted. The dose should be increased based on urinary citrate excretion.</p>
              </list-item>
              <list-item>
                <p>In older children and adults, potassium citrate tablets can be started at a dose of 10 mEq/3x/day. Citrate use should be monitored as it can cause hypertension and life-threatening hyperkalemia in affected individuals with renal impairment. Sodium levels should also be monitored.</p>
              </list-item>
            </list>
            <p><bold>Angiotensin-converting enzyme (ACE) inhibitors</bold> such as captopril are used to treat microalbuminuria, an early indicator of renal dysfunction.</p>
            <p><bold>Kidney transplantation</bold> can be performed for ESRD.</p>
            <p><bold>Hepatic adenomas</bold> can be treated with surgery or other interventions including percutaneous ethanol injections and radiofrequency ablation.</p>
            <p><bold>Liver transplantation</bold> can be considered when other interventions have failed.</p>
            <p><bold>Human granulocyte colony-stimulating factor (G-CSF)</bold> can be used to treat recurrent infections:</p>
            <list list-type="bullet">
              <list-item>
                <p>G-CSF may increase the number and improve the function of circulating neutrophils.</p>
              </list-item>
              <list-item>
                <p>G-CSF may improve the symptoms of Crohn's-like inflammatory bowel disease in individuals with GSDIb.</p>
              </list-item>
              <list-item>
                <p>G-CSF should be administered subcutaneously starting at 1.0 &#x003bc;g/kg given daily or every other day. The G-CSF dose should be increased stepwise at approximately two-week intervals until the target absolute neutrophil count (ANC) of greater than 500 to up to 1.0 x 10<sup>9</sup>/L is reached.</p>
              </list-item>
            </list>
            <p>Standard management of individuals with platelet dysfunction/von Willebrand disease include <bold>antifibrinolytics</bold> and <bold>deamino-8-d-arginine vasopressin (DDAVP),</bold> which acts by stimulating factor VIII from endothelial cells and improving von Willebrand factor activity and the platelet release reaction. However, DDAVP should be used with caution due to the risk for fluid overload and hyponatremia.</p>
          </sec>
        </sec>
        <sec id="gsd1.Prevention_of_Primary_Manifestation">
          <title>Prevention of Primary Manifestations</title>
          <p>See <xref ref-type="sec" rid="gsd1.Treatment_of_Manifestations">Treatment of Manifestations</xref>.</p>
        </sec>
        <sec id="gsd1.Prevention_of_Secondary_Complicatio">
          <title>Prevention of Secondary Complications</title>
          <p>Improve hyperuricemia and hyperlipidemia and maintain normal renal function to prevent the development of renal disease.</p>
          <p>Maintain lipid levels within the normal range to prevent atherosclerosis and pancreatitis.</p>
        </sec>
        <sec id="gsd1.Surveillance">
          <title>Surveillance</title>
          <p>Follow <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.nature.com/gim/journal/v16/n11/full/gim2014128a.html">GSDI guidelines</ext-link> published recently through a group of experts in the field [<xref ref-type="bibr" rid="gsd1.REF.kishnani.2014.e1">Kishnani et al 2014</xref>].</p>
          <p><bold>Annual ultrasound examination of the kidneys</bold> for nephrocalcinosis should be initiated after the first decade of life.</p>
          <p><bold>Surveillance of the liver</bold> may include the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>In younger children (age &#x0003c;16 years), liver ultrasound performed at diagnosis and thereafter every 12 to 24 months. In affected individuals who are 16 years and older, liver computed tomography (CT) or magnetic resonance imaging (MRI) scanning using intravenous contrast should be done every six to 12 months to monitor for hepatic adenoma formation [<xref ref-type="bibr" rid="gsd1.REF.franco.2005.153">Franco et al 2005</xref>].</p>
            </list-item>
            <list-item>
              <p>Hepatic profile: serum AST, ALT, albumin, bilirubin, PT/INR, and aPTT, and creatinine every six to 12 months to monitor for liver damage</p>
            </list-item>
            <list-item>
              <p><bold>When hepatic adenoma is detected.</bold> Abdominal CT/MRI with contrast should be performed in older individuals or individuals within the pediatric age group once adenomas are detected on ultrasound. Imaging should be repeated every 6-12 months or more often depending on laboratory and clinical findings. Liver imaging studies (MRI/CT scan) should evaluate liver size, adenomas, evidence of portal hypertension, or features suggestive of liver carcinoma (nodules, heterogeneous echogenic shadows) [<xref ref-type="bibr" rid="gsd1.REF.franco.2005.153">Franco et al 2005</xref>].</p>
              <p>Note: Serum AFP and CEA levels are not reliable markers of hepatocellular carcinoma [<xref ref-type="bibr" rid="gsd1.REF.shieh.2012.154">Shieh et al 2012</xref>].</p>
            </list-item>
          </list>
          <p><bold>For those individuals treated with G-CSF</bold> serial blood counts should be performed approximately every three months to assess response to treatment and, although the risk of acute myeloid leukemia (AML) is low, to evaluate for the presence of myeloblasts in the blood. Any imaging performed for liver surveillance (e.g., ultrasound, CT, or MRI) should include measurements of the spleen to identify and monitor splenomegaly.</p>
          <p>
            <bold>Cardiovascular surveillance</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Systemic blood pressure measurements should be obtained at all clinic visits beginning in infancy.</p>
            </list-item>
            <list-item>
              <p>Screening for pulmonary hypertension by echocardiography every three years beginning at age ten years (or earlier if symptoms are present) is appropriate.</p>
            </list-item>
          </list>
          <p><bold>25(OH)-vitamin D levels</bold> should be monitored routinely and treated as needed.</p>
        </sec>
        <sec id="gsd1.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Maintain a low-sucrose, low-fructose diet.</p>
          <p>Limit galactose and lactose intake to one serving per day.</p>
          <p>Due to potential negative effects of sex hormones on hepatic adenomas, combined oral contraception must be avoided in women with GSDI, especially those with adenomas [<xref ref-type="bibr" rid="gsd1.REF.sechi.2013.83">Sechi et al 2013</xref>, <xref ref-type="bibr" rid="gsd1.REF.austin.2013.1246">Austin et al 2013</xref>].</p>
        </sec>
        <sec id="gsd1.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>Evaluation of sibs of a proband as early as possible allows for prompt diagnosis and treatment with much-improved outcome. Evaluations include:</p>
          <list list-type="bullet">
            <list-item>
              <p>Molecular genetic testing if the pathogenic variants in the family are known;</p>
            </list-item>
            <list-item>
              <p>Evaluation by a metabolic physician soon after birth for symptoms pertaining to GSDI if the family-specific pathogenic variants are not known or if molecular genetic testing is not available.</p>
            </list-item>
          </list>
          <p>See <xref ref-type="sec" rid="gsd1.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="gsd1.Pregnancy_Management">
          <title>Pregnancy Management</title>
          <p>Although successful pregnancies have been reported in women with GSDI, certain precautions should be taken:</p>
          <list list-type="bullet">
            <list-item>
              <p>Pre-pregnancy counseling regarding diet to avoid low blood glucose and to stress the importance of blood glucose monitoring prior to and during pregnancy</p>
            </list-item>
            <list-item>
              <p>Baseline ultrasound of liver and kidneys prior to pregnancy</p>
            </list-item>
            <list-item>
              <p>Consideration of referral to high-risk obstetrician</p>
            </list-item>
            <list-item>
              <p>Review of medications prior to conception to weigh risks and benefits:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Exposure to ACE inhibitors in the second and third trimesters of pregnancy can cause fetal damage and death.</p>
                </list-item>
                <list-item>
                  <p>No data on the use of allopurinol during pregnancy in humans exist; however, high doses have been shown to interfere with embryo development in animal models.</p>
                </list-item>
                <list-item>
                  <p>Lipid-lowering drugs may also lead to adverse fetal effects and should be avoided during pregnancy.</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p>Metabolic control should be followed closely throughout the pregnancy. Because carbohydrate requirements may increase with pregnancy, glucose levels should be monitored closely and treated accordingly [<xref ref-type="bibr" rid="gsd1.REF.martens.2008.646.e1">Martens et al 2008</xref>, <xref ref-type="bibr" rid="gsd1.REF.dagli.2010.s151">Dagli et al 2010</xref>, <xref ref-type="bibr" rid="gsd1.REF.yamamoto.2010.1125">Yamamoto et al 2010</xref>, <xref ref-type="bibr" rid="gsd1.REF.ferrecchia.2014.26">Ferrecchia et al 2014</xref>].</p>
          <p>Abdominal ultrasound should be performed every six to 12 weeks. <xref ref-type="bibr" rid="gsd1.REF.sechi.2013.83">Sechi et al [2013]</xref> reported an increase in the size of pre-existent adenomas and the development of new adenomas during pregnancy and recommended monitoring by imaging before, during, and after pregnancy. Resection of large (&#x02265;5 cm) or growing adenomas before pregnancy has been recommended [<xref ref-type="bibr" rid="gsd1.REF.terkivatan.2000.186">Terkivatan et al 2000</xref>].</p>
          <p>Renal function should be followed closely, as this may worsen during pregnancy [<xref ref-type="bibr" rid="gsd1.REF.martens.2008.646.e1">Martens et al 2008</xref>, <xref ref-type="bibr" rid="gsd1.REF.dagli.2010.s151">Dagli et al 2010</xref>, <xref ref-type="bibr" rid="gsd1.REF.yamamoto.2010.1125">Yamamoto et al 2010</xref>]. Development of renal calculi has been reported in pregnant women with GSDIb [<xref ref-type="bibr" rid="gsd1.REF.dagli.2010.s151">Dagli et al 2010</xref>].</p>
          <p>Glucose infusion during labor has been used [<xref ref-type="bibr" rid="gsd1.REF.martens.2008.646.e1">Martens et al 2008</xref>, <xref ref-type="bibr" rid="gsd1.REF.dagli.2010.s151">Dagli et al 2010</xref>, <xref ref-type="bibr" rid="gsd1.REF.ferrecchia.2014.26">Ferrecchia et al 2014</xref>].</p>
          <p>Platelet count, hemoglobin, and clotting studies should be performed because of the potential for increased bleeding at delivery [<xref ref-type="bibr" rid="gsd1.REF.lewis.2005.111">Lewis et al 2005</xref>].</p>
        </sec>
        <sec id="gsd1.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Current dietary treatment prevents hypoglycemia and greatly improves the life expectancy of individuals with GSDI. However, long-term complications, such as development of hepatic adenomas that progress to hepatocellular carcinoma (HCC), and progressive renal failure, still occur. The development of new therapies for GSDI has focused on correcting the primary cause of these disorders and avoiding long-term complications. Pilot studies of hepatocyte transplantation have shown that donor cells persist. However, further studies are needed to investigate the long-term efficacy of this approach [<xref ref-type="bibr" rid="gsd1.REF.lee.2007.629">Lee et al 2007</xref>, <xref ref-type="bibr" rid="gsd1.REF.ribeskoninckx.2012.2267">Ribes-Koninckx et al 2012</xref>]. Gene therapy strategies for GSDIa and GSDIb have focused, most recently, on recombinant adeno-associated virus (rAAV) vectors. These studies have shown promising results in animal models [<xref ref-type="bibr" rid="gsd1.REF.chou.2011.1011">Chou &#x00026; Mansfield 2011</xref>, <xref ref-type="bibr" rid="gsd1.REF.chou.2015.511">Chou et al 2015</xref>]. Increased hepatic G6Pase and G6PT activity and improvement of metabolic parameters has been observed using rAAV-mediated G6PC gene transfer in animal models. However, transgene expression decreased over time, indicating that repeated administration may be necessary for long-term treatment in humans. Strategies to integrate the G6Pase transgene into the genome are being investigated, with promising results [<xref ref-type="bibr" rid="gsd1.REF.landau.2016.697">Landau et al 2016</xref>]. Of note, a relatively low level (3% of normal) of hepatic G6Pase activity is needed for survival and to prevent formation of hepatocellular adenomas [<xref ref-type="bibr" rid="gsd1.REF.lee.2015.28">Lee at al 2015</xref>]. Correction of renal G6Pase deficiency by gene therapy has been less well studied, and the most efficient methods for transducing kidney cells continue to be investigated [<xref ref-type="bibr" rid="gsd1.REF.chou.2015.511">Chou et al 2015</xref>]. Identification of AAV serotypes that effectively transduce all affected tissue types (including liver, kidney, and hematopoietic stem cells) would be beneficial [<xref ref-type="bibr" rid="gsd1.REF.chou.2015.511">Chou et al 2015</xref>].</p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
      </sec>
      <sec id="gsd1.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="gsd1.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Glycogen storage disease type I (GSDI) is inherited in an autosomal recessive manner.</p>
        </sec>
        <sec id="gsd1.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected child are obligate heterozygotes (i.e., carriers of one <italic toggle="yes">G6PC</italic> or <italic toggle="yes">SLC37A4</italic> pathogenic variant).</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> The offspring of an individual with GSDI are obligate heterozygotes (carriers) for a pathogenic variant in <italic toggle="yes">G6PC</italic> or <italic toggle="yes">SLC37A4</italic>.</p>
          <p><bold>Other family members of a proband.</bold> Each sib of the proband's parents is at a 50% risk of being a carrier in <italic toggle="yes">G6PC</italic> or <italic toggle="yes">SLC37A4</italic>.</p>
        </sec>
        <sec id="gsd1.Carrier_Heterozygote_Detection">
          <title>Carrier (Heterozygote) Detection</title>
          <p><bold>Molecular genetic testing.</bold> Carrier testing for at-risk relatives requires prior identification of the <italic toggle="yes">G6PC</italic> or <italic toggle="yes">SLC37A4</italic> pathogenic variants in the family.</p>
          <p><bold>Biochemical genetic testing.</bold> Enzymatic testing is unreliable and not available for use in carrier detection.</p>
        </sec>
        <sec id="gsd1.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="gsd1.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on testing at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="gsd1.Prenatal_Testing_and_Preimplantatio">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p><bold>Molecular genetic testing.</bold> Once the <italic toggle="yes">G6PC</italic> or <italic toggle="yes">SLC37A4</italic> pathogenic variants have been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic diagnosis are possible.</p>
          <p><bold>Biochemical testing.</bold> Prenatal testing based on assay of G6Pase enzymatic activity or G6P translocase enzymatic activity is not available because of the low accuracy rate and risk associated with fetal liver biopsy. The G6Pase enzyme assay in vitro may not differentiate a carrier from either a normal or an affected pregnancy [<xref ref-type="bibr" rid="gsd1.REF.chen.2002.357">Chen et al 2002</xref>] and thus is not recommended.</p>
          <p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions about prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p>
        </sec>
      </sec>
      <sec id="gsd1.Resources">
        <title>Resources</title>
      </sec>
      <sec id="gsd1.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p>
          <bold>
            <italic toggle="yes">G6PC</italic>
          </bold>
        </p>
        <p><bold>Gene structure.</bold>
<italic toggle="yes">G6PC</italic> spans approximately 12.5 kb and consists of five exons. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="gsd1" object-id="gsd1.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Pathogenic allelic variants.</bold> More than 100 pathogenic variants that are scattered throughout the gene have been reported (see <related-object source-id="gene" document-id="gsd1" object-id="gsd1.molgen.TA">Table A</related-object>). These pathogenic variants include missense and nonsense variants, small deletions and insertions, splice site variants (see <xref ref-type="table" rid="gsd1.T.g6pc_pathogenic_variants_discusse">Table 2</xref>), and other rare large gene rearrangements (See <xref ref-type="table" rid="gsd1.T.molecular_genetic_testing_used_in">Table 1</xref>).</p>
        <p>The following are some ethnic-specific common pathogenic variants that account for approximately 90% of known disease alleles [<xref ref-type="bibr" rid="gsd1.REF.veigadacunha.1998.976">Veiga-da-Cunha et al 1998</xref>, <xref ref-type="bibr" rid="gsd1.REF.chou.2002.121">Chou et al 2002</xref>, <xref ref-type="bibr" rid="gsd1.REF.matern.2002.s10">Matern et al 2002</xref>, <xref ref-type="bibr" rid="gsd1.REF.chou.2008.921">Chou &#x00026; Mansfield 2008</xref>].</p>
        <list list-type="bullet">
          <list-item>
            <p>c.247C&#x0003e;T (European origin 32%, Jewish 93%-100%) [<xref ref-type="bibr" rid="gsd1.REF.stroppiano.1999.43">Stroppiano et al 1999</xref>, <xref ref-type="bibr" rid="gsd1.REF.janecke.2001.117">Janecke et al 2001</xref>, <xref ref-type="bibr" rid="gsd1.REF.ekstein.2004.162">Ekstein et al 2004</xref>]</p>
          </list-item>
          <list-item>
            <p>c.248G&#x0003e;A (Chinese 38%)</p>
          </list-item>
          <list-item>
            <p>c.379_380dupTA (Hispanic 50%) [<xref ref-type="bibr" rid="gsd1.REF.rake.1999.173">Rake et al 1999</xref>, <xref ref-type="bibr" rid="gsd1.REF.matern.2002.s10">Matern et al 2002</xref>]</p>
          </list-item>
          <list-item>
            <p>c.648G&#x0003e;T (Japanese 88%, Chinese 36%) [<xref ref-type="bibr" rid="gsd1.REF.kajihara.1995.549">Kajihara et al 1995</xref>, <xref ref-type="bibr" rid="gsd1.REF.lam.1998.184">Lam et al 1998</xref>]</p>
          </list-item>
          <list-item>
            <p>c.79delC, c.562G&#x0003e;C, and c.1039C&#x0003e;T (European origin 21%) [<xref ref-type="bibr" rid="gsd1.REF.seydewitz.2000.115">Seydewitz &#x00026; Matern 2000</xref>, <xref ref-type="bibr" rid="gsd1.REF.chou.2002.121">Chou et al 2002</xref>]</p>
          </list-item>
        </list>
        <table-wrap id="gsd1.T.g6pc_pathogenic_variants_discusse" orientation="portrait" position="anchor">
          <label>Table 2. </label>
          <caption>
            <p><italic toggle="yes">G6PC</italic> Pathogenic Variants Discussed in This <italic toggle="yes">GeneReview</italic></p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_gsd1.T.g6pc_pathogenic_variants_discusse_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change<break/>(Alias&#x000a0;<sup>1</sup>)</th>
                <th id="hd_h_gsd1.T.g6pc_pathogenic_variants_discusse_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                <th id="hd_h_gsd1.T.g6pc_pathogenic_variants_discusse_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_gsd1.T.g6pc_pathogenic_variants_discusse_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.79delC<break/>(158delC)</td>
                <td headers="hd_h_gsd1.T.g6pc_pathogenic_variants_discusse_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gln27ArgfsTer9</td>
                <td headers="hd_h_gsd1.T.g6pc_pathogenic_variants_discusse_1_1_1_3" rowspan="7" valign="middle" align="left" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_000151.3">NM_000151.3</ext-link>
                  <break/>
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&#x00026;id=4557599">NP_000142.1</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_gsd1.T.g6pc_pathogenic_variants_discusse_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.247C&#x0003e;T</td>
                <td headers="hd_h_gsd1.T.g6pc_pathogenic_variants_discusse_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg83Cys</td>
              </tr>
              <tr>
                <td headers="hd_h_gsd1.T.g6pc_pathogenic_variants_discusse_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.248G&#x0003e;A</td>
                <td headers="hd_h_gsd1.T.g6pc_pathogenic_variants_discusse_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg83His</td>
              </tr>
              <tr>
                <td headers="hd_h_gsd1.T.g6pc_pathogenic_variants_discusse_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.562G&#x0003e;C<break/>(641G&#x0003e;C)</td>
                <td headers="hd_h_gsd1.T.g6pc_pathogenic_variants_discusse_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gly188Arg</td>
              </tr>
              <tr>
                <td headers="hd_h_gsd1.T.g6pc_pathogenic_variants_discusse_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.648G&#x0003e;T<break/>(G727T)</td>
                <td headers="hd_h_gsd1.T.g6pc_pathogenic_variants_discusse_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Tyr202Ter&#x000a0;<sup>2</sup></td>
              </tr>
              <tr>
                <td headers="hd_h_gsd1.T.g6pc_pathogenic_variants_discusse_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1039C&#x0003e;T<break/>(1118C&#x0003e;T)</td>
                <td headers="hd_h_gsd1.T.g6pc_pathogenic_variants_discusse_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gln347Ter&#x000a0;<sup>3</sup></td>
              </tr>
              <tr>
                <td headers="hd_h_gsd1.T.g6pc_pathogenic_variants_discusse_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.379_380dupTA<break/>(459insTA)</td>
                <td headers="hd_h_gsd1.T.g6pc_pathogenic_variants_discusse_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Tyr128ThrfsTer3</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
            </fn>
            <fn>
              <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
            </fn>
            <fn id="gsd1.TF.2.1">
              <label>1. </label>
              <p>Variant designation that does not conform to current naming conventions</p>
            </fn>
            <fn id="gsd1.TF.2.2">
              <label>2. </label>
              <p>Silent amino acid change (Leu216Leu) that creates a new splice site resulting in premature termination at p.Tyr202Ter [<xref ref-type="bibr" rid="gsd1.REF.lam.1998.184">Lam et al 1998</xref>]</p>
            </fn>
            <fn id="gsd1.TF.2.3">
              <label>3. </label>
              <p>See <xref ref-type="sec" rid="gsd1.Establishing_the_Diagnosis">Establishing the Diagnosis</xref>.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold>Normal gene product.</bold> G6Pase is a multi-component enzyme system localized in the endoplasmic reticulum membrane. It helps catalyze the terminal reaction of both glucogenolysis and gluconeogenesis, hydrolyzing G6P to glucose and inorganic phosphate in hepatocytes and renal cells.</p>
        <p><bold>Abnormal gene product.</bold> The pathogenic variants in the G6Pase system cause deficiency of the catalytic activity of the enzyme, thus preventing release of free glucose in the affected tissues (liver, kidney, intestinal mucosa).</p>
        <p>
          <bold>
            <italic toggle="yes">SLC37A4</italic>
          </bold>
        </p>
        <p><bold>Gene structure.</bold>
<italic toggle="yes">SLC37A4</italic> spans approximately 5.3 kb and comprises nine exons [<xref ref-type="bibr" rid="gsd1.REF.veigadacunha.1998.976">Veiga-da-Cunha et al 1998</xref>, <xref ref-type="bibr" rid="gsd1.REF.veigadacunha.2000.314">Veiga-da-Cunha et al 2000</xref>, <xref ref-type="bibr" rid="gsd1.REF.chou.2002.121">Chou et al 2002</xref>, <xref ref-type="bibr" rid="gsd1.REF.matern.2002.s10">Matern et al 2002</xref>]. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="gsd1" object-id="gsd1.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Pathogenic allelic variants.</bold> More than 100 pathogenic variants are known (see <related-object source-id="gene" document-id="gsd1" object-id="gsd1.molgen.TA">Table A</related-object>). Most are nucleotide substitutions resulting in pathogenic missense or nonsense variants. Some small deletions, splicing variants, and one large deletion have also been found [<xref ref-type="bibr" rid="gsd1.REF.janecke.2000.285">Janecke et al 2000</xref>, <xref ref-type="bibr" rid="gsd1.REF.qiu.2011.203">Qiu et al 2011</xref>] (see <xref ref-type="table" rid="gsd1.T.slc37a4_pathogenic_variants_discu">Table 3</xref>).</p>
        <p>Some ethnic-specific common pathogenic variants:</p>
        <list list-type="bullet">
          <list-item>
            <p>c.1015G&#x0003e;T (European origin 15%, German 29%) and c.1042_1043delCT (European origin 31%, German 32%) [<xref ref-type="bibr" rid="gsd1.REF.veigadacunha.1999.717">Veiga-da-Cunha et al 1999</xref>, <xref ref-type="bibr" rid="gsd1.REF.santer.2000.177">Santer et al 2000</xref>, <xref ref-type="bibr" rid="gsd1.REF.chou.2002.121">Chou et al 2002</xref>]</p>
          </list-item>
          <list-item>
            <p>c.352T&#x0003e;C (50% Japanese) [<xref ref-type="bibr" rid="gsd1.REF.kure.1998.426">Kure et al 1998</xref>, <xref ref-type="bibr" rid="gsd1.REF.nakamura.1999.553">Nakamura et al 1999</xref>, <xref ref-type="bibr" rid="gsd1.REF.matern.2002.s10">Matern et al 2002</xref>, <xref ref-type="bibr" rid="gsd1.REF.kojima.2004.343">Kojima et al 2004</xref>]</p>
          </list-item>
        </list>
        <table-wrap id="gsd1.T.slc37a4_pathogenic_variants_discu" orientation="portrait" position="anchor">
          <label>Table 3. </label>
          <caption>
            <p><italic toggle="yes">SLC37A4</italic> Pathogenic Variants Discussed in This <italic toggle="yes">GeneReview</italic></p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_gsd1.T.slc37a4_pathogenic_variants_discu_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change<break/>(Alias&#x000a0;<sup>1</sup>)</th>
                <th id="hd_h_gsd1.T.slc37a4_pathogenic_variants_discu_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                <th id="hd_h_gsd1.T.slc37a4_pathogenic_variants_discu_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_gsd1.T.slc37a4_pathogenic_variants_discu_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.352T&#x0003e;C<break/>(521T&#x0003e;C)</td>
                <td headers="hd_h_gsd1.T.slc37a4_pathogenic_variants_discu_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Trp118Arg</td>
                <td headers="hd_h_gsd1.T.slc37a4_pathogenic_variants_discu_1_1_1_3" rowspan="3" valign="middle" align="left" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_001467.5">NM_001467.5</ext-link>
                  <break/>
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&#x00026;id=4503847">NP_001458.1</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_gsd1.T.slc37a4_pathogenic_variants_discu_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1015G&#x0003e;T<break/>(1184G&#x0003e;T)</td>
                <td headers="hd_h_gsd1.T.slc37a4_pathogenic_variants_discu_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gly339Cys</td>
              </tr>
              <tr>
                <td headers="hd_h_gsd1.T.slc37a4_pathogenic_variants_discu_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1042_1043delCT<break/>(1211delCT)</td>
                <td headers="hd_h_gsd1.T.slc37a4_pathogenic_variants_discu_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Leu348ValfsTer53</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
            </fn>
            <fn>
              <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
            </fn>
            <fn id="gsd1.TF.3.1">
              <label>1. </label>
              <p>Variant designation that does not conform to current naming conventions</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold>Normal gene product.</bold> Glucose-6-phosphate exchanger SLC37A4 (transporter) produces a transport protein that helps transport G6P into the lumen of the endoplasmic reticulum from the cytoplasm and endoplasmic reticulum membrane compartment. G6P transporter is expressed ubiquitously in tissues such as liver, kidney, large intestine, small intestine, skeletal muscle, and (to a lesser extent) the brain and heart, unlike G6Pase.</p>
        <p><bold>Abnormal gene product.</bold> Deficiency of G6P transporter prevents G6P from crossing the microsomal membrane for hydrolysis and production of glucose.</p>
      </sec>
      <sec id="gsd1.References">
        <title>References</title>
        <sec id="gsd1.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="gsd1.Literature_Cited.reflist0">
            <ref id="gsd1.REF.akanuma.2000.107">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Akanuma</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nishigaki</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fujii</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matsubara</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Inui</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takahashi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kure</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ohura</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miyabayashi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ogawa</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iinuma</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Okada</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Narisawa</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <article-title>Glycogen storage disease type Ia: molecular diagnosis of 51 Japanese patients and characterization of splicing mutations by analysis of ectopically transcribed mRNA from lymphoblastoid cells.</article-title>
                <source>Am J Med Genet.</source>
                <year>2000</year>
                <volume>91</volume>
                <fpage>107</fpage>
                <lpage>12</lpage>
                <pub-id pub-id-type="pmid">10748407</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.austin.2013.1246">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Austin</surname>
                    <given-names>SL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>El-Gharbawy</surname>
                    <given-names>AH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kasturi</surname>
                    <given-names>VG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>James</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kishnani</surname>
                    <given-names>PS</given-names>
                  </name>
                </person-group>
                <article-title>Menorrhagia in patients with type I glycogen storage disease.</article-title>
                <source>Obstet Gynecol</source>
                <year>2013</year>
                <volume>122</volume>
                <fpage>1246</fpage>
                <lpage>54</lpage>
                <pub-id pub-id-type="pmid">24201678</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.banugaria.2010.434">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Banugaria</surname>
                    <given-names>SG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Austin</surname>
                    <given-names>SL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boney</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weber</surname>
                    <given-names>TJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kishnani</surname>
                    <given-names>PS</given-names>
                  </name>
                </person-group>
                <article-title>Hypovitaminosis D in glycogen storage disease type I.</article-title>
                <source>Mol Genet Metab.</source>
                <year>2010</year>
                <volume>99</volume>
                <fpage>434</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">20060350</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.beegle.2015.23">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Beegle</surname>
                    <given-names>RD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brown</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weinstein</surname>
                    <given-names>DA</given-names>
                  </name>
                </person-group>
                <article-title>Regression of hepatocellular adenomas with strict dietary therapy in patients with glycogen storage disease type I.</article-title>
                <source>JIMD Rep.</source>
                <year>2015</year>
                <volume>18</volume>
                <fpage>23</fpage>
                <lpage>32</lpage>
                <pub-id pub-id-type="pmid">25308557</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.bolz.1996.265">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bolz</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stocker</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zimmermann</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>Pulmonary vascular disease in a child with atrial septal defect of the secundum type and type I glycogen storage disease.</article-title>
                <source>Pediatr Cardiol.</source>
                <year>1996</year>
                <volume>17</volume>
                <fpage>265</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">8662053</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.cabreraabreu.2004.1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cabrera-Abreu</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crabtree</surname>
                    <given-names>NJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elias</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fraser</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cramb</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alger</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Bone mineral density and markers of bone turnover in patients with glycogen storage disease types I, III and IX.</article-title>
                <source>J Inherit Metab Dis</source>
                <volume>27</volume>
                <fpage>1</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">14970741</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.chen.2002.357">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>YT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bali</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sullivan</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Prenatal diagnosis in glycogen storage diseases.</article-title>
                <source>Prenat Diagn</source>
                <volume>22</volume>
                <fpage>357</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">12001186</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.chou.2015.511">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chou</surname>
                    <given-names>JY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jun</surname>
                    <given-names>HS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mansfield</surname>
                    <given-names>BC</given-names>
                  </name>
                </person-group>
                <article-title>Type I glycogen storage diseases: disorders of the glucose-6-phosphatase/glucose-6-phosphate transporter complexes.</article-title>
                <source>J Inherit Metab Dis.</source>
                <year>2015</year>
                <volume>38</volume>
                <fpage>511</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">25288127</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.chou.2002.121">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chou</surname>
                    <given-names>JY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matern</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mansfield</surname>
                    <given-names>BC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>YT</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Type I glycogen storage diseases: disorders of the glucose-6-phosphatase complex.</article-title>
                <source>Curr Mol Med</source>
                <volume>2</volume>
                <fpage>121</fpage>
                <lpage>43</lpage>
                <pub-id pub-id-type="pmid">11949931</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.chou.2008.921">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chou</surname>
                    <given-names>JY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mansfield</surname>
                    <given-names>BC</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Mutations in the glucose-6-phosphatase-alpha (G6PC) gene that cause type Ia glycogen storage disease.</article-title>
                <source>Hum Mutat.</source>
                <volume>29</volume>
                <fpage>921</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">18449899</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.chou.2011.1011">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chou</surname>
                    <given-names>JY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mansfield</surname>
                    <given-names>BC</given-names>
                  </name>
                </person-group>
                <article-title>Recombinant AAV-directed gene therapy for type I glycogen storage diseases.</article-title>
                <source>Expert Opin Biol Ther.</source>
                <year>2011</year>
                <volume>11</volume>
                <fpage>1011</fpage>
                <lpage>24</lpage>
                <pub-id pub-id-type="pmid">21504389</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.dagli.2010.s151">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Dagli</surname>
                    <given-names>AI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Correia</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodriguez</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bhattacharya</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steinkrauss</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stanley</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weinstein</surname>
                    <given-names>DA</given-names>
                  </name>
                </person-group>
                <article-title>Pregnancy in glycogen storage disease type Ib: gestational care and report of first successful deliveries.</article-title>
                <source>J Inherit Metab Dis.</source>
                <year>2010</year>
                <volume>33</volume>
                <supplement>Suppl 3</supplement>
                <fpage>S151</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">20386986</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.di_rocco.2007.42">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Di Rocco</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buzzi</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tar&#x000f2;</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Glycogen storage disease type II: clinical overview.</article-title>
                <source>Acta Myol.</source>
                <year>2007</year>
                <volume>26</volume>
                <fpage>42</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">17915568</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.ekstein.2004.162">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ekstein</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rubin</surname>
                    <given-names>BY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anderson</surname>
                    <given-names>SL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weinstein</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bach</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abeliovich</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Webb</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Risch</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Mutation frequencies for glycogen storage disease Ia in the Ashkenazi Jewish population.</article-title>
                <source>Am J Med Genet A.</source>
                <volume>129A</volume>
                <fpage>162</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">15316959</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.eminoglu.2013.346">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Eminoglu</surname>
                    <given-names>TF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ezgu</surname>
                    <given-names>FS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hasanoglu</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tumer</surname>
                    <given-names>L</given-names>
                  </name>
                </person-group>
                <article-title>Rapid screening of 12 common mutations in Turkish GSD 1a patients using electronic DNA microarray.</article-title>
                <source>Gene.</source>
                <year>2013</year>
                <volume>518</volume>
                <fpage>346</fpage>
                <lpage>50</lpage>
                <pub-id pub-id-type="pmid">23352793</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.ferrecchia.2014.26">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ferrecchia</surname>
                    <given-names>IA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guenette</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Potocik</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weinstein</surname>
                    <given-names>DA</given-names>
                  </name>
                </person-group>
                <article-title>Pregnancy in women with glycogen storage disease Ia and Ib.</article-title>
                <source>J Perinat Neonatal Nurs.</source>
                <year>2014</year>
                <volume>28</volume>
                <fpage>26</fpage>
                <lpage>31</lpage>
                <pub-id pub-id-type="pmid">24476649</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.franco.2005.153">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Franco</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krishnamurthy</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bali</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weinstein</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arn</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clary</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boney</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sullivan</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frush</surname>
                    <given-names>DP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>YT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kishnani</surname>
                    <given-names>PS</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Hepatocellular carcinoma in glycogen storage disease type Ia: a case series.</article-title>
                <source>J Inherit Metab Dis</source>
                <volume>28</volume>
                <fpage>153</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">15877204</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.furukawa.1990.102">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Furukawa</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kinugasa</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Inoue</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Imashuku</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takamatsu</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sawada</surname>
                    <given-names>T.</given-names>
                  </name>
                </person-group>
                <article-title>Type I glycogen storage disease with vasoconstrictive pulmonary hypertension.</article-title>
                <source>J Inherit Metab Dis.</source>
                <year>1990</year>
                <volume>13</volume>
                <fpage>102</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">2109144</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.hamaoka.1990.54">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hamaoka</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakagawa</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Furukawa</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sawada</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <article-title>Pulmonary hypertension in type I glycogen storage disease.</article-title>
                <source>Pediatr Cardiol.</source>
                <year>1990</year>
                <volume>11</volume>
                <fpage>54</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">2304882</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.humbert.2002.s93">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Humbert</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Labrune</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simonneau</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Severe pulmonary arterial hypertension in type 1 glycogen storage disease.</article-title>
                <source>Eur J Pediatr.</source>
                <volume>161</volume>
                <supplement>Suppl 1</supplement>
                <fpage>S93</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">12373580</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.iida.2003.56">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Iida</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matsuoka</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Inoue</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tomiyasu</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Noda</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Calcium nephrolithiasis and distal tubular acidosis in type 1 glycogen storage disease.</article-title>
                <source>Int J Urol</source>
                <volume>10</volume>
                <fpage>56</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">12534929</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.janecke.2000.285">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Janecke</surname>
                    <given-names>AR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lindner</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Erdel</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mayatepek</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000f6;slinger</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Podskarbi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fresser</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>St&#x000f6;ckler-Ipsiroglu</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoffmann</surname>
                    <given-names>GF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Utermann</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Mutation analysis in glycogen storage disease type 1 non-a.</article-title>
                <source>Hum Genet.</source>
                <volume>107</volume>
                <fpage>285</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">11071391</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.janecke.2001.117">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Janecke</surname>
                    <given-names>AR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mayatepek</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Utermann</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Molecular genetics of type 1 glycogen storage disease.</article-title>
                <source>Mol Genet Metab</source>
                <volume>73</volume>
                <fpage>117</fpage>
                <lpage>25</lpage>
                <pub-id pub-id-type="pmid">11386847</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.kajihara.1995.549">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kajihara</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matsuhashi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamamoto</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kido</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsuji</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tanae</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fujiyama</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Itoh</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tanigawa</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uchida</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Setoguchi</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Motomura</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mizuta</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sakai</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>1995</year>
                <article-title>Exon redefinition by a point mutation within exon 5 of the glucose-6-phosphatase gene is the major cause of glycogen storage disease type 1a in Japan.</article-title>
                <source>Am J Hum Genet</source>
                <volume>57</volume>
                <fpage>549</fpage>
                <lpage>55</lpage>
                <pub-id pub-id-type="pmid">7668282</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.kelly.2001.505">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kelly</surname>
                    <given-names>PM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poon</surname>
                    <given-names>FW</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Hepatic tumours in glycogen storage disease type 1 (von Gierke's disease).</article-title>
                <source>Clin Radiol</source>
                <volume>56</volume>
                <fpage>505</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">11428803</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.kishnani.2014.e1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kishnani</surname>
                    <given-names>PS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Austin</surname>
                    <given-names>SL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abdenur</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arn</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bali</surname>
                    <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boney</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chung</surname>
                    <given-names>WK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dagli</surname>
                    <given-names>AI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dale</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koeberl</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Somers</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wechsler</surname>
                    <given-names>SB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weinstein</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wolfsdorf</surname>
                    <given-names>JI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Watson</surname>
                    <given-names>MS</given-names>
                  </name>
                </person-group>
                <article-title>Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics.</article-title>
                <source>Genet Med.</source>
                <year>2014</year>
                <volume>16</volume>
                <fpage>e1</fpage>
                <pub-id pub-id-type="pmid">25356975</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.kishnani.1996.213">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kishnani</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bengur</surname>
                    <given-names>AR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>YT</given-names>
                  </name>
                </person-group>
                <article-title>Pulmonary hypertension in glycogen storage disease type I.</article-title>
                <source>J Inherit Metab Dis.</source>
                <year>1996</year>
                <volume>19</volume>
                <fpage>213</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">8739968</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.kojima.2004.343">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kojima</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kure</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kamada</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hao</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ichinohe</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sato</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aoki</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoichi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kubota</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Horikawa</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Utsumi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miura</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ogawa</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kanazawa</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kohno</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Inokuchi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hasegawa</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Narisawa</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matsubara</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Genetic testing of glycogen storage disease type Ib in Japan: five novel G6PT1 mutations and a rapid detection method for a prevalent mutation W118R.</article-title>
                <source>Mol Genet Metab</source>
                <volume>81</volume>
                <fpage>343</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">15059622</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.kudo.2001.65">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kudo</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Hepatocellular adenoma in type Ia glycogen storage disease.</article-title>
                <source>J Gastroenterol</source>
                <volume>36</volume>
                <fpage>65</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">11211215</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.kure.1998.426">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kure</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matsubara</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sakamoto</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shintaku</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Isshiki</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoshida</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Izumi</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sakura</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Narisawa</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Molecular analysis of glycogen storage disease type Ib: identification of a prevalent mutation among Japanese patients and assignment of a putative glucose-6-phosphate translocase gene to chromosome 11.</article-title>
                <source>Biochem Biophys Res Commun</source>
                <volume>248</volume>
                <fpage>426</fpage>
                <lpage>31</lpage>
                <pub-id pub-id-type="pmid">9675154</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.lam.1998.184">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lam</surname>
                    <given-names>CW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>But</surname>
                    <given-names>WM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shek</surname>
                    <given-names>CC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tong</surname>
                    <given-names>SF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chan</surname>
                    <given-names>YS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Choy</surname>
                    <given-names>KW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tse</surname>
                    <given-names>WY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pang</surname>
                    <given-names>CP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hjelm</surname>
                    <given-names>NM</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Glucose-6-phosphatase gene (727G--&#x0003e;T) splicing mutation is prevalent in Hong Kong Chinese patients with glycogen storage disease type 1a.</article-title>
                <source>Clin Genet</source>
                <volume>53</volume>
                <fpage>184</fpage>
                <lpage>90</lpage>
                <pub-id pub-id-type="pmid">9630072</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.landau.2016.697">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Landau</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brooks</surname>
                    <given-names>ED</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Perez-Pinera</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amarasekara</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mefferd</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bird</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gersbach</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koeberl</surname>
                    <given-names>DD</given-names>
                  </name>
                </person-group>
                <article-title>In Vivo Zinc Finger Nuclease-mediated Targeted Integration of a Glucose-6-phosphatase Transgene Promotes Survival in Mice With Glycogen Storage Disease Type IA.</article-title>
                <source>Mol Ther.</source>
                <year>2016</year>
                <volume>24</volume>
                <fpage>697</fpage>
                <lpage>706</lpage>
                <pub-id pub-id-type="pmid">26865405</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.lee.2015.28">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>YM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kim</surname>
                    <given-names>GY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pan</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mansfield</surname>
                    <given-names>BC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chou</surname>
                    <given-names>JY</given-names>
                  </name>
                </person-group>
                <article-title>Minimal hepatic glucose-6-phosphatase-&#x003b1; activity required to sustain survival and prevent hepatocellular adenoma formation in murine glycogen storage disease type Ia.</article-title>
                <source>Mol Genet Metab Rep.</source>
                <year>2015</year>
                <volume>3</volume>
                <fpage>28</fpage>
                <lpage>32</lpage>
                <pub-id pub-id-type="pmid">26937391</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.lee.2007.629">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>KW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shin</surname>
                    <given-names>SW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kim</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Joh</surname>
                    <given-names>JW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>DH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kim</surname>
                    <given-names>JW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Park</surname>
                    <given-names>HY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>SY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>HH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Park</surname>
                    <given-names>JW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kim</surname>
                    <given-names>SY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoon</surname>
                    <given-names>HH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jung</surname>
                    <given-names>DH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Choe</surname>
                    <given-names>YH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>SK</given-names>
                  </name>
                </person-group>
                <article-title>Hepatocyte transplantation for glycogen storage disease type Ib.</article-title>
                <source>Cell Transplant.</source>
                <year>2007</year>
                <volume>16</volume>
                <fpage>629</fpage>
                <lpage>37</lpage>
                <pub-id pub-id-type="pmid">17912954</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.lewis.2005.111">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lewis</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scrutton</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Standen</surname>
                    <given-names>GR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murphy</surname>
                    <given-names>DJ</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Antenatal and Intrapartum care of a pregnant woman with glycogen storage disease type 1a.</article-title>
                <source>Eur J Obstet Gynecol Reprod Biol.</source>
                <volume>118</volume>
                <fpage>111</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">15596284</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.martens.2008.646.e1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Martens</surname>
                    <given-names>DH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rake</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwarz</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ullrich</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weinstein</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Merkel</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sauer</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smit</surname>
                    <given-names>GP</given-names>
                  </name>
                </person-group>
                <article-title>Pregnancies in glycogen storage disease type Ia.</article-title>
                <source>Am J Obstet Gynecol.</source>
                <year>2008</year>
                <volume>198</volume>
                <fpage>646.e1</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">18241814</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.matern.2002.s10">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Matern</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seydewitz</surname>
                    <given-names>HH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bali</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lang</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>YT</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Glycogen storage disease type I: diagnosis and phenotype/genotype correlation.</article-title>
                <source>Eur J Pediatr</source>
                <volume>161</volume>
                <supplement>Suppl 1</supplement>
                <fpage>S10</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">12373566</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.melis.2005.501">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Melis</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fulceri</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parenti</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marcolongo</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gatti</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parini</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Riva</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Della Casa</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zammarchi</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andria</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Benedetti</surname>
                    <given-names>A.</given-names>
                  </name>
                </person-group>
                <article-title>Genotype/phenotype correlation in glycogen storage disease type 1b: a multicentre study and review of the literature.</article-title>
                <source>Eur J Pediatr.</source>
                <year>2005</year>
                <volume>164</volume>
                <fpage>501</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">15906092</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.melis.2004.637">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Melis</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parenti</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Della Casa</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sibilio</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Romano</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Di Salle</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elefante</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mansi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santoro</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Perretti</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paludetto</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sequino</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andria</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Brain damage in glycogen storage disease type I.</article-title>
                <source>J Pediatr</source>
                <volume>144</volume>
                <fpage>637</fpage>
                <lpage>42</lpage>
                <pub-id pub-id-type="pmid">15127000</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.melis.2007.300">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Melis</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pivonello</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parenti</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Della Casa</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salerno</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lombardi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sebastio</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Colao</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andria</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <article-title>Increased prevalence of thyroid autoimmunity and hypothyroidism in patients with glycogen storage disease type I.</article-title>
                <source>J Pediatr.</source>
                <year>2007</year>
                <volume>150</volume>
                <fpage>300</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">17307551</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.mortellaro.2005.45">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mortellaro</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garagiola</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carbone</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cerutti</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marci</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonda</surname>
                    <given-names>PL</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Unusual oral manifestations and evolution in glycogen storage disease type Ib.</article-title>
                <source>J Craniofac Surg</source>
                <volume>16</volume>
                <fpage>45</fpage>
                <lpage>52</lpage>
                <pub-id pub-id-type="pmid">15699644</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.mundy.2003.332">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mundy</surname>
                    <given-names>HR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hindmarsh</surname>
                    <given-names>PC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matthews</surname>
                    <given-names>DR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leonard</surname>
                    <given-names>JV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>PJ</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>The regulation of growth in glycogen storage disease type 1.</article-title>
                <source>Clin Endocrinol (Oxf)</source>
                <volume>58</volume>
                <fpage>332</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">12608939</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.nakamura.2001.1402">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nakamura</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ozawa</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kawasaki</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakamura</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sugimura</surname>
                    <given-names>H.</given-names>
                  </name>
                </person-group>
                <article-title>Glucose-6-phosphatase gene mutations in 20 adult Japanese patients with glycogen storage disease type 1a with reference to hepatic tumors.</article-title>
                <source>J Gastroenterol Hepatol.</source>
                <year>2001</year>
                <volume>16</volume>
                <fpage>1402</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">11851840</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.nakamura.1999.553">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nakamura</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ozawa</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kawasaki</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yasumi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>DY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kitagawa</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takehira</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tamakoshi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamada</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kida</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sugie</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakamura</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sugimura</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Case report: Hepatocellular carcinoma in type 1a glycogen storage disease with identification of a glucose-6-phosphatase gene mutation in one family.</article-title>
                <source>J Gastroenterol Hepatol</source>
                <volume>14</volume>
                <fpage>553</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">10385064</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.pizzo.1980.341">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pizzo</surname>
                    <given-names>CJ</given-names>
                  </name>
                </person-group>
                <article-title>Type I glycogen storage disease with focal nodular hyperplasia of the liver and vasoconstrictive pulmonary hypertension.</article-title>
                <source>Pediatrics.</source>
                <year>1980</year>
                <volume>65</volume>
                <fpage>341</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">6928317</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.qiu.2011.203">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Qiu</surname>
                    <given-names>ZQ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lu</surname>
                    <given-names>CX</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Qiu</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wei</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Mutation in the SLC37A4 gene of glycogen storage disease type Ib in 15 families of the mainland of China.</article-title>
                <source>Zhonghua Er Ke Za Zhi.</source>
                <year>2011</year>
                <volume>49</volume>
                <fpage>203</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">21575371</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.rake.1999.173">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rake</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>ten Berge</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verlind</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Visser</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Niezen-Koning</surname>
                    <given-names>KE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buys</surname>
                    <given-names>CH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smit</surname>
                    <given-names>GP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scheffer</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Glycogen storage disease type Ia: four novel mutations (175delGG, R170X, G266V and V338F) identified. Mutations in brief no. 220. Online.</article-title>
                <source>Hum Mutat.</source>
                <year>1999</year>
                <volume>13</volume>
                <fpage>173</fpage>
                <pub-id pub-id-type="pmid">10094563</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.rake.2000.322">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rake</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>ten Berge</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Visser</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verlind</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Niezen-Koning</surname>
                    <given-names>KE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buys</surname>
                    <given-names>CH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smit</surname>
                    <given-names>GP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scheffer</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Glycogen storage disease type Ia: recent experience with mutation analysis, a summary of mutations reported in the literature and a newly developed diagnostic flow chart.</article-title>
                <source>Eur J Pediatr</source>
                <volume>159</volume>
                <fpage>322</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">10834516</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.rake.2003.371">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rake</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Visser</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huismans</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huitema</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Veer</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Piers</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smit</surname>
                    <given-names>GP</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Bone mineral density in children, adolescents and adults with glycogen storage disease type Ia: a cross-sectional and longitudinal study.</article-title>
                <source>J Inherit Metab Dis</source>
                <volume>26</volume>
                <fpage>371</fpage>
                <lpage>84</lpage>
                <pub-id pub-id-type="pmid">12971425</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.rake.2002.s20">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rake</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Visser</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Labrune</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leonard</surname>
                    <given-names>JV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ullrich</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smit</surname>
                    <given-names>GP</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I).</article-title>
                <source>Eur J Pediatr.</source>
                <volume>161</volume>
                <supplement>Suppl 1</supplement>
                <fpage>S20</fpage>
                <lpage>34</lpage>
                <pub-id pub-id-type="pmid">12373567</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.ribeskoninckx.2012.2267">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ribes-Koninckx</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ibars</surname>
                    <given-names>EP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Calzado Agrasot</surname>
                    <given-names>M&#x000c1;</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonora-Centelles</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miquel</surname>
                    <given-names>BP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vila Carb&#x000f3;</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aliaga</surname>
                    <given-names>ED</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pallard&#x000f3;</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>G&#x000f3;mez-Lech&#x000f3;n</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Castell</surname>
                    <given-names>JV</given-names>
                  </name>
                </person-group>
                <article-title>Clinical outcome of hepatocyte transplantation in four pediatric patients with inherited metabolic diseases.</article-title>
                <source>Cell Transplant.</source>
                <year>2012</year>
                <volume>21</volume>
                <fpage>2267</fpage>
                <lpage>82</lpage>
                <pub-id pub-id-type="pmid">23231960</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.ross.2016.85">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ross</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brown</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corrado</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chengsupanimit</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Curry</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferrecchia</surname>
                    <given-names>IA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Porras</surname>
                    <given-names>LY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mathew</surname>
                    <given-names>JT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weinstein</surname>
                    <given-names>DA</given-names>
                  </name>
                </person-group>
                <year>2016</year>
                <article-title>Safety and Efficacy of Chronic Extended Release Cornstarch Therapy for Glycogen Storage Disease Type I.</article-title>
                <source>JIMD Rep.</source>
                <year>2016</year>
                <volume>26</volume>
                <fpage>85</fpage>
                <lpage>90</lpage>
                <pub-id pub-id-type="pmid">26303612</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.santer.2000.177">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Santer</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rischewski</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Block</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kinner</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wendel</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schaub</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schneppenheim</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <article-title>Molecular analysis in glycogen storage disease 1 non-A: DHPLC detection of the highly prevalent exon 8 mutations of the G6PT1 gene in German patients.</article-title>
                <source>Hum Mutat</source>
                <year>2000</year>
                <volume>16</volume>
                <fpage>177</fpage>
                <pub-id pub-id-type="pmid">10923042</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.schwahn.2002.350">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schwahn</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rauch</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wendel</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schonau</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Low bone mass in glycogen storage disease type 1 is associated with reduced muscle force and poor metabolic control.</article-title>
                <source>J Pediatr</source>
                <volume>141</volume>
                <fpage>350</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">12219054</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.sechi.2013.83">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sechi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deroma</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lapolla</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paci</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Melis</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burlina</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carubbi</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rigoldi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Di Rocco</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Fertility and pregnancy in women affected by glycogen storage disease type I, results of a multicenter Italian study.</article-title>
                <source>J Inherit Metab Dis.</source>
                <year>2013</year>
                <volume>36</volume>
                <fpage>83</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">22562700</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.seydewitz.2000.115">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Seydewitz</surname>
                    <given-names>HH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matern</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Molecular genetic analysis of 40 patients with glycogen storage disease type Ia: 100% mutation detection rate and 5 novel mutations.</article-title>
                <source>Hum Mutat</source>
                <volume>15</volume>
                <fpage>115</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">10612834</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.shieh.2012.154">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Shieh</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lu</surname>
                    <given-names>YH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huang</surname>
                    <given-names>SW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huang</surname>
                    <given-names>YH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sun</surname>
                    <given-names>CH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chiou</surname>
                    <given-names>HJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liu</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lo</surname>
                    <given-names>MY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lin</surname>
                    <given-names>CY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Niu</surname>
                    <given-names>DM</given-names>
                  </name>
                </person-group>
                <article-title>Misdiagnosis as steatohepatitis in a family with mild glycogen storage disease type 1a.</article-title>
                <source>Gene.</source>
                <year>2012</year>
                <volume>509</volume>
                <fpage>154</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">22909800</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.sim_es.2001.1277">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sim&#x000f6;es</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Domingos</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fortes</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prata</surname>
                    <given-names>MM</given-names>
                  </name>
                </person-group>
                <article-title>Type 1 glycogen storage disease and recurrent calcium nephrolithiasis.</article-title>
                <source>Nephrol Dial Transplant.</source>
                <year>2001</year>
                <volume>16</volume>
                <fpage>1277</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">11390734</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.stroppiano.1999.43">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Stroppiano</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Regis</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DiRocco</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caroli</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gandullia</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gatti</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Mutations in the glucose-6-phosphatase gene of 53 Italian patients with glycogen storage disease type Ia.</article-title>
                <source>J Inherit Metab Dis</source>
                <volume>22</volume>
                <fpage>43</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">10070617</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.terkivatan.2000.186">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Terkivatan</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Wilt</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Man</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ijzermans</surname>
                    <given-names>JN</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Management of hepatocellular adenoma during pregnancy.</article-title>
                <source>Liver.</source>
                <volume>20</volume>
                <fpage>186</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">10847490</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.veigadacunha.1998.976">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Veiga-da-Cunha</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gerin</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>YT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Barsy</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Lonlay</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dionisi-Vici</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fenske</surname>
                    <given-names>CD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leonard</surname>
                    <given-names>JV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maire</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McConkie-Rosell</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schweitzer</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vikkula</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Schaftingen</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>A gene on chromosome 11q23 coding for a putative glucose- 6-phosphate translocase is mutated in glycogen-storage disease types Ib and Ic.</article-title>
                <source>Am J Hum Genet</source>
                <volume>63</volume>
                <fpage>976</fpage>
                <lpage>83</lpage>
                <pub-id pub-id-type="pmid">9758626</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.veigadacunha.1999.717">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Veiga-da-Cunha</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gerin</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>YT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leonard</surname>
                    <given-names>JV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maire</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wendel</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vikkula</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Schaftingen</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>The putative glucose 6-phosphate translocase gene is mutated in essentially all cases of glycogen storage disease type I non-a.</article-title>
                <source>Eur J Hum Genet</source>
                <volume>7</volume>
                <fpage>717</fpage>
                <lpage>23</lpage>
                <pub-id pub-id-type="pmid">10482962</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.veigadacunha.2000.314">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Veiga-da-Cunha</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gerin</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Schaftingen</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>How many forms of glycogen storage disease type I?</article-title>
                <source>Eur J Pediatr</source>
                <volume>159</volume>
                <fpage>314</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">10834514</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.visser.2012.287">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Visser</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Jager</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verhagen</surname>
                    <given-names>LP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smit</surname>
                    <given-names>GP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wijburg</surname>
                    <given-names>FA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prakken</surname>
                    <given-names>BJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coffer</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buitenhuis</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Survival, but not maturation, is affected in neutrophil progenitors from GSD-1b patients.</article-title>
                <source>J Inherit Metab Dis.</source>
                <year>2012</year>
                <volume>35</volume>
                <fpage>287</fpage>
                <lpage>300</lpage>
                <pub-id pub-id-type="pmid">21863279</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.visser.1998.227">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Visser</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Herwig</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rake</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Niezen-Koning</surname>
                    <given-names>KE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verhoeven</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smit</surname>
                    <given-names>GP</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Neutropenia and neutrophil dysfunction in glycogen storage disease type 1c.</article-title>
                <source>J Inherit Metab Dis</source>
                <volume>21</volume>
                <fpage>227</fpage>
                <lpage>31</lpage>
                <pub-id pub-id-type="pmid">9686363</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.visser.2002a.261">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Visser</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rake</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kokke</surname>
                    <given-names>FT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nikkels</surname>
                    <given-names>PG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sauer</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smit</surname>
                    <given-names>GP</given-names>
                  </name>
                </person-group>
                <year>2002a</year>
                <article-title>Intestinal function in glycogen storage disease type I.</article-title>
                <source>J Inherit Metab Dis</source>
                <volume>25</volume>
                <fpage>261</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">12227456</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.visser.2002b.s83">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Visser</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rake</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Labrune</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leonard</surname>
                    <given-names>JV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moses</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ullrich</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wendel</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Groenier</surname>
                    <given-names>KH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smit</surname>
                    <given-names>GP</given-names>
                  </name>
                </person-group>
                <year>2002b</year>
                <article-title>Granulocyte colony-stimulating factor in glycogen storage disease type 1b. Results of the European Study on Glycogen Storage Disease Type 1.</article-title>
                <source>Eur J Pediatr.</source>
                <volume>161</volume>
                <supplement>Suppl 1</supplement>
                <fpage>S83</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">12373578</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.wang.2012.795">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>DQ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carreras</surname>
                    <given-names>CT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fiske</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Austin</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boree</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kishnani</surname>
                    <given-names>PS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weinstein</surname>
                    <given-names>DA</given-names>
                  </name>
                </person-group>
                <article-title>Characterization and pathogenesis of anemia in glycogen storage disease type Ia and Ib.</article-title>
                <source>Genet Med.</source>
                <year>2012</year>
                <volume>14</volume>
                <fpage>795</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">22678084</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.wang.2011.442">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>DQ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fiske</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carreras</surname>
                    <given-names>CT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weinstein</surname>
                    <given-names>DA</given-names>
                  </name>
                </person-group>
                <article-title>Natural history of hepatocellular adenoma formation in glycogen storage disease type I.</article-title>
                <source>J Pediatr.</source>
                <year>2011</year>
                <volume>159</volume>
                <fpage>442</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">21481415</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.weinstein.2002.s35">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Weinstein</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wolfsdorf</surname>
                    <given-names>JI</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Effect of continuous glucose therapy with uncooked cornstarch on the long-term clinical course of type 1a glycogen storage disease.</article-title>
                <source>Eur J Pediatr.</source>
                <volume>161</volume>
                <supplement>Suppl 1</supplement>
                <fpage>S35</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">12373568</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.weston.2000.329">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Weston</surname>
                    <given-names>BW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lin</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muenzer</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cameron</surname>
                    <given-names>HS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arnold</surname>
                    <given-names>RR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seydewitz</surname>
                    <given-names>HH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mayatepek</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Schaftingen</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Veiga-Da-Cunha</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matern</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>YT</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Glucose-6-phosphatase mutation G188R confers an atypical glycogen storage disease type Ib phenotype.</article-title>
                <source>Pediatr Res</source>
                <volume>48</volume>
                <fpage>329</fpage>
                <lpage>34</lpage>
                <pub-id pub-id-type="pmid">10960498</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.wolfsdorf.2002.308">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wolfsdorf</surname>
                    <given-names>JI</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Bones benefit from better biochemical control in type 1 glycogen storage disease.</article-title>
                <source>J Pediatr</source>
                <volume>141</volume>
                <fpage>308</fpage>
                <lpage>10</lpage>
                <pub-id pub-id-type="pmid">12219049</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.wolfsdorf.1999.136">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wolfsdorf</surname>
                    <given-names>JI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crigler</surname>
                    <given-names>JF</given-names>
                    <suffix>Jr</suffix>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Effect of continuous glucose therapy begun in infancy on the long-term clinical course of patients with type I glycogen storage disease.</article-title>
                <source>J Pediatr Gastroenterol Nutr</source>
                <volume>29</volume>
                <fpage>136</fpage>
                <lpage>43</lpage>
                <pub-id pub-id-type="pmid">10435649</pub-id>
              </element-citation>
            </ref>
            <ref id="gsd1.REF.yamamoto.2010.1125">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yamamoto</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaneko</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hattori</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Obayashi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzumori</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sugiura</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Glycogen storage disease type Ia (GSD Ia) during pregnancy: report of a case complicated by fetal growth restriction and preeclampsia.</article-title>
                <source>J Obstet Gynaecol Res.</source>
                <year>2010</year>
                <volume>36</volume>
                <fpage>1125</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">21058447</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="gsd1.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="gsd1.Acknowledgments">
          <title>Acknowledgments</title>
          <p>We acknowledge the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.agsdus.org">Association for Glycogen Storage Disease</ext-link>, individuals with GSD, physicians treating individuals with GSD, and laboratory personnel for their untiring work and cooperation.</p>
        </sec>
        <sec id="gsd1.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>25 August 2016 (sw) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>19 September 2013 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>23 December 2010 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>2 September 2008 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>19 April 2006 (me) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>30 March 2005 (ytc) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
